Fusion protein for treating rejection reaction in transplantation

ABSTRACT

The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present disclosure relates to the field of pharmaceuticals; moreparticularly, to multi-functional molecular constructs, e.g., thosehaving targeting and effector elements for delivering the effector(e.g., therapeutic drug) to targeted sites.

2. Description of the Related Art

The continual advancement of a broad array of methodologies forscreening and selecting monoclonal antibodies (mAbs) for targetedantigens has helped the development of a good number of therapeuticantibodies for many diseases that were regarded as untreatable just afew years ago. According to Therapeutic Antibody Database, approximately2,800 antibodies have been studied or are being planned for studies inhuman clinical trials, and approximately 80 antibodies have beenapproved by governmental drug regulatory agencies for clinical uses. Thelarge amount of data on the therapeutic effects of antibodies hasprovided information concerning the pharmacological mechanisms howantibodies act as therapeutics.

One major pharmacologic mechanism for antibodies acting as therapeuticsis that, antibodies can neutralize or trap disease-causing mediators,which may be cytokines or immune components present in the bloodcirculation, interstitial space, or in the lymph nodes. The neutralizingactivity inhibits the interaction of the disease-causing mediators withtheir receptors. It should be noted that fusion proteins of the solublereceptors or the extracellular portions of receptors of cytokines andthe Fc portion of IgG, which act by neutralizing the cytokines or immunefactors in a similar fashion as neutralizing antibodies, have also beendeveloped as therapeutic agents.

Several therapeutic antibodies that have been approved for clinicalapplications or subjected to clinical developments mediate theirpharmacologic effects by binding to receptors, thereby blocking theinteraction of the receptors with their ligands. For those antibodydrugs, Fc-mediated mechanisms, such as antibody-dependent cellularcytotoxicity (ADCC) and complement-mediated cytolysis (CMC), are not theintended mechanisms for the antibodies.

Some therapeutic antibodies bind to certain surface antigens on targetcells and render Fc-mediated functions and other mechanisms on thetarget cells. The most important Fc-mediated mechanisms areantibody-dependent cellular cytotoxicity (ADCC) and complement-mediatedcytolysis (CMC), which both will cause the lysis of the antibody-boundtarget cells. Some antibodies binding to certain cell surface antigenscan induce apoptosis of the bound target cells.

The concept and methodology for preparing antibodies with dualspecificities germinated more than three decades ago. In recent year,the advancement in recombinant antibody engineering methodologies andthe drive to develop improved medicine has stimulated the developmentbi-specific antibodies adopting a large variety of structuralconfigurations.

For example, the bi-valent or multivalent antibodies may contain two ormore antigen-binding sites. A number of methods have been reported forpreparing multivalent antibodies by covalently linking three or four Fabfragments via a connecting structure.

For example, antibodies have been engineered to express tandem three orfour Fab repeats.

Several methods for producing multivalent antibodies by employingsynthetic crosslinkers to associate, chemically, different antibodies orbinding fragments have been disclosed. One approach involves chemicallycross-linking three, four, and more separately Fab fragments usingdifferent linkers. Another method to produce a construct with multipleFabs that are assembled to one-dimensional DNA scaffold was provided.Those various multivalent Ab constructs designed for binding to targetmolecules differ among one another in size, half-lives, flexibility inconformation, and ability to modulate the immune system. In view of theforegoing, several reports have been made for preparing molecularconstructs with a fixed number of effector elements or with two or moredifferent kinds of functional elements (e.g., at least one targetingelement and at least one effector element). However, it is oftendifficult to build a molecular construct with a particular combinationof the targeting and effector elements either using chemical synthesisor recombinant technology. Accordingly, there exists a need in therelated art to provide novel molecular platforms to build a moreversatile molecule suitable for covering applications in a wide range ofdiseases.

SUMMARY

The following presents a simplified summary of the disclosure in orderto provide a basic understanding to the reader. This summary is not anextensive overview of the disclosure and it does not identifykey/critical elements of the present invention or delineate the scope ofthe present invention. Its sole purpose is to present some conceptsdisclosed herein in a simplified form as a prelude to the more detaileddescription that is presented later.

<I> Peptide Core-Based Multi-Arm Linkers for Treating Rejection Reactionin Transplantation and Uses Thereof

In the first aspect, the present disclosure is directed to a linker unitfor treating transplantation rejection in a subject. In particular, thelinker unit has at least two different functional elements linkedthereto. For example, the linker unit may have linked thereto twodifferent effector elements, one targeting element and one effectorelement, or one effector element and a polyethylene glycol (PEG) chainfor prolonging the circulation time of the linker unit. The presentlinker unit is designed to have at least two different functional groupssuch that the functional elements can be linked thereto by reacting withthe respective functional groups. Accordingly, the present linker unitcan serve as a platform for preparing a molecular construct with two ormore functional elements. As could be appreciated, methods for treatinga transplant patient using such linker unit also fall within the aspectof the present disclosure

According to various embodiments of the present disclosure, the linkerunit comprises a center core, a plurality of linking arms, a pluralityof first elements, and optionally, a coupling arm and a second element.

According to various embodiments of the present disclosure, the centercore is a peptide core having a pre-defined number of amine (—NH₂)groups, before being linked with the linking arms. For example, thepeptide core may have two or more lysine (K) resides having an amine(—NH₂) group at the side chain.

In certain embodiments, the peptide core comprises 2 to 15 K resides andone or more filler sequences, in which each K residue and a next Kresidue are separated by one of the filler sequences. Each of the fillersequences comprises glycine (G) and serine (S) residues. Optionally, thefiller sequence consists of 2 to 20 amino acid residues. In variousembodiments, the filler sequence may have the sequence of GS, GGS, GSG,or SEQ ID NOs: 1-16. In certain embodiments of the present disclosure,at least one of the filler sequences in one peptide core differs fromthe remaining filler sequences of the same peptide core. According tosome embodiments of the present disclosure, the peptide core comprises 2to 15 units of the sequence of G₁₋₅SK; preferably, the peptide corecomprises the sequence of (GSK)₂₋₁₅.

According to some other embodiments, the peptide core comprises thesequence of (X_(aa)-K)₂₋₁₅, in which X_(aa) is a PEGylated amino acidhaving 2 to 12 repeats of ethylene glycol (EG) unit.

Each of the linking arms is linked to the amine groups of the centercore via forming an amide linkage between the amine group and thelinking arm. As could be appreciated, in the case of a peptide core, thelinking arm is linked to the center core by reacting with the aminegroup at the side chain of the K residue. Further, the linking armlinked to the center core has a maleimide, an N-hydroxysuccinimidyl(NHS) group, an azide group, an alkyne group, a tetrazine group, acyclooctene group, or a cyclooctyne group at its free-terminus.

On the other hand, for the peptide core, the amino acid residue at theN- or C-terminus of the center core has an azide group or an alkynegroup; alternatively or additionally, the amino acid residue at the N-or C-terminus of the center core is a cysteine (C) residue.

According to certain embodiments of the present disclosure, when thecenter core is a peptide core having a terminal amino acid residue ofCysteine, the present linker unit comprises said coupling arm. Forpeptide cores with terminal the terminal amino acid residue of Cysteine,one end of the coupling arm is linked to the Cysteine residue byreacting with the thiol group thereof.

Regarding amino acid residues having the azide group, non-limitingexamples of said amino acid residues include L-azidohomoalanine (AHA),4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine,3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine,5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, and6-azido-D-lysine. As to the amino acid residues having the alkyne group,illustrative examples thereof include L-homopropargylglycine (L-HPG),D-homopropargylglycine (D-HPG), and beta-homopropargylglycine (β-HPG).

When the amino acid residues at the N- or C-terminus of the center coreis the cysteine residue, the cyclooctene group at the free terminus ofthe coupling arm may be, a trans-cyclooctene (TCO) group, while thecyclooctyne group at the free terminus of the coupling arm may be adibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO),bicyclononyne (BCN), or dibenzocyclooctyne (DICO) group. Alternatively,the tetrazine group at the free terminus of the coupling arm includes,but is not limited to, 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, and1,2,4,5-tetrazine, and derivatives thereof, such as, 6-methyl tetrazine.

In some embodiments, the linking arm is a PEG chain, preferably having 2to 20 repeats of EG units. In other embodiments, the coupling linkingarm is a PEG chain, preferably having 2 to 12 repeats of EG units.

According to various optional embodiments of the present disclosure, thefirst element is an effector element suitable for eliciting an intendedeffect (e.g., a therapeutic effect) in a subject. Alternatively, thefirst element may be a targeting element for directing the linker unitto the site of interest. In preferred embodiments, when the firstelement is the effector element, the second element is the targetingelement, and vice versa.

Specifically, the targeting element according to various embodiments ofthe present disclosure is an antibody fragment specific for a humanleukocyte antigen (HLA) allotype present only on cells of the donortransplant and not on cells of the recipient, such as the HLA-A, HLA-B,and HLA-C allotype. Also, the effector element is an immunosuppressant,an immune checkpoint protein, or an antibody fragment specific for CD25.Illustrative examples of immunosuppressant are inhibitors of mammaliantarget of rapamycin (mTOR), e.g. sirolimus and everolimus. Another setof immunosuppressants are inhibitors of calcineurin, e.g. tacrolimus.Fingolimod and derivatives thereof (e.g., fingolimod phosphate) are alsoexamples of suitable immunosuppressants Immune checkpoint proteins arethose involve in immune checkpoint, such as the extracellular domain ofcytotoxic T lymphocyte associated protein 4 (CTLA-4, also known asCD151) and the extracellular domain of programmed death-ligand 1 (PD-L1,also known as CD274).

In some embodiments, each of the first elements is linked to one of thelinking arms via forming an amide bound between the linking arm and thefirst element. In other embodiments, each of the first elements islinked to one of the linking arms via thiol-maleimide reaction, coppercatalyzed azide-alkyne cycloaddition (CuAAC) reaction, strained-promotedazide-alkyne click chemistry (SPAAC) reaction, or inverse electrondemand Diels-Alder (iEDDA) reaction occurred between the linking arm andthe first element.

According to some embodiments of the present disclosure, when theplurality of first elements are respectively linked to the plurality oflinking arms via CuAAC or SPAAC reaction, then the amino acid residue atthe N- or C-terminus of the center core is a cysteine residue, and thefree terminus of the coupling arm is the tetrazine or the cyclooctenegroup. According to other embodiments of the present disclosure, whenthe plurality of first elements are respectively linked to the pluralityof linking arms via iEDDA reaction, then the amino acid residue at theN- or C-terminus of the center core has the azide or the alkyne group,or the amino acid residue at the N- or C-terminus of the center core isa cysteine residue, and the free terminus of the coupling arm is theazide, the alkyne, or the cyclooctyne group.

In some embodiments, the second element has an azide or alkyne group, sothat it is linked to the center core or the coupling arm by couplingwith the corresponding alkyne or azide group of the center core or thecoupling arm via CuAAC reaction. Alternatively, in other embodiments,the second element having an azide or cyclooctyne group is linked to thecenter core or the coupling arm by coupling with the correspondingcyclooctyne or azide group of the center core or the coupling arm viaSPAAC reaction. Still alternatively, in certain embodiments, the secondelement having a tetrazine or cyclooctene group is linked to the centercore or the coupling arm by coupling with the corresponding cycloocteneor tetrazine group of the center core or the coupling arm via iEDDAreaction.

In certain embodiments, the linker unit further comprises an optionalthird element that is different from the first and second elements. Inthe case where the second element is directly linked to the center core,the other terminus (i.e., the free terminus that is not linked with thesecond element) of the center core is optionally a cysteine residue,which can be used to introduce an optional third element. Specifically,the thiol group of the cysteine residue is reacted with a maleimidegroup of a PEG chain; and the thus-linked PEG chain is designated as thecoupling arm, which has a tetrazine group or a cyclooctene group at itsfree terminus. Accordingly, the third element is then linked to thecoupling arm via iEDDA reaction. Preferably, the third element is anelement for improving the pharmacokinetic property of the linker unit.One example of the element for improving the pharmacokinetic property isa long PEG chain having a molecular weight of about 20,000 to 50,000Daltons.

The linker unit according to this aspect of the present disclosure mayfind its utility in clinical medicine for the treatment oftransplantation rejection. Accordingly, the present disclosure is alsodirected to a method for suppressing or inhibiting transplantationrejection in a subject receiving a donor transplant (e.g., organ, tissueor cells), or for use in the manufacture of a medicament for such uses.According to various embodiments of the present disclosure, the methodfor treating the transplantation rejection in a particular subjectincludes the step of administering to the subject in need thereof atherapeutically effective amount of the linker unit according to theabove-mentioned aspect and embodiments of the present disclosure. Ascould be appreciated, said linker unit may be administered in apharmaceutical formulation, which comprises apharmaceutically-acceptable excipient suitable for the intended ordesired administration route, in addition to the present linker unit.

<II> Fc-based Molecular Construct for Treating Rejection Reaction inTransplantation and Uses Thereof

In this aspect, the present disclosure is directed to a fragmentcrystallizable (Fc)-based molecular construct that has at least onetargeting element and at least one effector element linked, directly orindirectly, to a CH2-CH3 domain of an immunoglobulin. Targeting andeffector elements of the present Fc-based molecular constructs arespecifically selected such that these Fc-based molecular constructs aresuitable for use in suppressing or inhibiting the transplantationrejection in a subject (or recipient) receiving an organ, tissue or celltransplantation, or for use in the manufacture of a medicament for suchuses. As could be appreciated, methods for treating transplantationrejection using such Fc-based molecular constructs also fall within theaspect of the present disclosure.

According to certain embodiments of the present disclosure, the Fc-basedmolecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, apair of effector elements, and a pair of targeting elements.

According to various embodiments of the present disclosure, the pair oftargeting elements is an antibody fragment specific for a humanleukocyte antigen (HLA) allotype present only on cells of the donortransplant and not on cells of the recipient, such as the HLA-A, HLA-B,and HLA-C allotype present only on cells of the donor transplant. Also,the pair of elements is an immune checkpoint protein, an antibodyfragment specific for CD25, or a drug bundle comprising animmunosuppressant. Immune checkpoint proteins are those involve inimmune checkpoint, such as the extracellular domain of cytotoxic Tlymphocyte associated protein 4 (CTLA-4, also known as CD151) and theextracellular domain of programmed death-ligand 1 (PD-L1, also known asCD274). Illustrative examples of immunosuppressant are inhibitors ofmammalian target of rapamycin (mTOR), e.g. sirolimus and everolimus.Another set of immunosuppressants are inhibitors of calcineurin, e.g.tacrolimus. Fingolimod and derivatives thereof (e.g., fingolimodphosphate) are also examples of suitable immunosuppressants

In the case where the effector element is the immune checkpoint protein,then the pair of effector elements is linked to the N-termini of thepair of CH2-CH3 segments, and the pair of targeting elements is linkedto the C-termini of the pair of CH2-CH3 segments, or vice versa.Alternatively, when the effector element is the drug bundle, then thepair of effector elements is linked to the C-termini of the pair ofCH2-CH3 segments, and the pair of targeting elements is linked to theN-termini of the pair of CH2-CH3 segments. Still alternatively, when theeffector elements are the antibody fragments, then the effector elementsis respectively linked to the N-termini of the pair of CH2-CH3 segments,and the targeting elements is respectively linked to the C-termini ofthe pair of CH2-CH3 segments, and vice versa.

According to certain embodiments, when the pair of effector elements andthe pair of targeting elements are both in the form of single-chainvariable fragments (scFvs), then the pair of targeting elements islinked to the N-termini of the pair of effector elements in a tandem ordiabody configuration, thereby forming a pair of bispecific scFvs thatare linked to the N-termini of the pair of CH2-CH3 segments.

In some examples, the pair of the targeting elements takes a Fabconfiguration (i.e., consisting of the V_(H)-CH1 domain and the V_(L)-Cκdomain); this Fab fragment is linked to the N-termini of the first andsecond heavy chains, so that the Fc-based molecular construct adopts anIgG configuration. In these cases, the pair of effector elements islinked to the C-termini of the pair of CH2-CH3 segments.

According to some other embodiments of the present disclosure, when thepair of effector elements is in the form of an antigen-binding fragment(Fab), and the pair of targeting elements is in the form of scFvs, andvice versa; then the Fab and scFvs are respectively linked to theN-termini and C-termini of the CH2-CH3 segments, so that the molecularconstruct adopts an extended IgG configuration.

In certain embodiments, the pair of CH2-CH3 segments is derived fromhuman IgG heavy chain γ4 or human IgG heavy chain γ1.

According to some optional embodiments, the effector elements are drugbundles based on linker units. Such drug bundles are advantageous atleast in that they can be manufactured separately before beingconjugated to the antibody molecules, thus avoiding subjecting drugmolecules under harsh chemical conditions for the direct conjugationwith the antibody molecules. According to various embodiments of thepresent disclosure, the drug bundle comprises a plurality ofimmunosuppressant molecules. As an example, rather than a limitation,these Fc-based molecular constructs are useful in the treatment oftransplantation rejection.

According to certain embodiments, the present Fc-based molecularconstruct further comprises a peptide extension and a coupling arm.Specifically, the peptide extension has the sequence of (G₂₋₄S)₂₋₈C andis linked to the C-terminus of one of the pair of CH2-CH3 segments. Insuch cases, the coupling arm is linked to the C-terminus of the peptideextension via thiol-maleimide reaction occurred therebetween. Also,before being conjugated with the drug bundle, the free terminus of thecoupling arm (that is, the terminus that is not linked to the cysteineresidue) is modified with an alkyne, azide, strained alkyne, ortetrazine group, so that the drug bundle is linked thereto via inverseelectron demand Diels-Alder (iEDDA) reaction or the strain-promotedazide-alkyne click chemistry (SPAAC) reaction or Copper(I)-catalyzedalkyne-azide cycloaddition (CuAAC) reaction occurred therebetween.

According to some optional embodiments, the drug bundle is a linkerunit-based molecular construct according to the first aspect andembodiments of the present disclosure.

Briefly, the center core may be a polypeptide comprising a plurality oflysine (K) residues, according to various embodiments of the presentdisclosure. Each of the linking arms has one terminus that is linked tothe center core by reacting with the amine groups at the side chain ofthe K residues of the polypeptide core. The linking arm also carries amaleimide group at the free terminus thereof, wherein each of themolecules (e.g., immunosuppressant molecules) is linked to the centercore through the linking arm by reacting with the maleimide group.

In the case where the center core is the polypeptide core, then theamino acid residue at the N- or C-terminus of the center core is acysteine residue or has an azide group or an alkyne group.

For polypeptide cores with a terminal amino acid residue having theazide group or the alkyne group, the drug bundle may be linked to thepeptide extension via the CuAAC reaction occurred between said terminalresidue and the C-terminus of the peptide extension.

Methods for suppressing or inhibiting transplantation rejection in asubject in need thereof comprise the step of administering to thesubject an effective amount of the molecular construct of this aspect.

BRIEF DESCRIPTION OF THE DRAWINGS

The present description will be better understood from the followingdetailed description read in light of the accompanying drawings brieflydiscussed below.

FIG. 1A to FIG. 1K are schematic diagrams illustrating linker unitsaccording to certain embodiments of the present disclosure.

FIGS. 2A to 2C are schematic diagrams illustrating Fc-based molecularconstructs according to various embodiments of the present disclosure.

FIG. 3 is a schematic diagram illustrating a Fc-based molecularconstruct according to some embodiments of the present disclosure.

FIGS. 4A to 4C are schematic diagrams illustrating Fc-based molecularconstructs according to various embodiments of the present disclosure.

FIGS. 5A and 5B are schematic diagrams illustrating Fc-based molecularconstructs according to various embodiments of the present disclosure.

FIG. 6A and FIG. 6B respectively show the mass spectrometric analysis ofthe sirolimus-Gly and sirolimus-diGly, according to one working exampleof the present disclosure.

FIG. 7A and FIG. 7B respectively show the MALDI-TOF analysis of theazido-PEG3-S-S-conjugated sirolimus-Gly and sirolimus-diGly, accordingto one working example of the present disclosure.

FIG. 8 shows the MALDI-TOF analysis of the NHS-PEG5-conjugatedfingolimod.

FIG. 9 shows the mass spectrometric analysis of theazido-PEG3-S-S-conjugated fingolimod according to one working example ofthe present disclosure.

FIG. 10A and FIG. 10B respectively show the mass spectrometric analysisof the NHS-PEG4-PEG3-S-S-conjugated sirolimus-Gly and sirolimus-diGly,according to one working example of the present disclosure.

FIG. 11 shows the mass spectrometric analysis of theNHS-PEG4-PEG3-S-S-conjugated fingolimod, according to one workingexample of the present disclosure.

FIGS. 12A to 12D respectively show the MALDI-TOF analysis of a drugbundle composing of a linker unit with a free TCO functional group and aset of five sirolimus-Gly, five fingolimod, ten fingolimod and fivefingolimod phosphate molecules, according to one working example of thepresent disclosure.

FIGS. 13A to 13C respectively show the SDS-PAGE analysis of purifiedhuman HLA-A1-IgG1.Fc, HLA-A2-IgG1.Fc and PD-1-IgG1.Fc fusion protein,according to one working example of the present disclosure.

FIGS. 14A and 14B respectively show the SDS-PAGE of purified humanCTLA-4 and PD-L1 proteins; FIG. 14C shows the western blot analysis ofpurified human CTLA-4; and FIG. 14D shows the ELISA analysis of purifiedhuman PD-L1 proteins, according to one working example of the presentdisclosure.

FIGS. 15A to 15C respectively show the SDS-PAGE, mass spectrometric andELISA analyses of purified scFv of mAb specific for human HLA-A1,according to one working example of the present disclosure.

FIGS. 16A and 16B respectively show the titers of the phages bearingscFvs specific for human HLA-A2 and the single colony ELISA analysis ofphage-displayed scFvs specific for human HLA-A2, according to oneworking example of the present disclosure.

FIG. 17A and FIG. 17B respectively show the mass spectrometric and ELISAanalysis of tetrazine-conjugated scFv specific for human HLA-A1,according to one working example of the present disclosure.

FIG. 18 shows the 10% SDS-PAGE analysis of an effector linker-unit,composed of a linker-unit with a free TCO functional group and a set ofthree PDL-1 molecules as effector elements, according to one workingexample of the present disclosure.

FIG. 19 shows the 10% SDS-PAGE analysis of a single linker unitmolecular construct with one scFv specific for HLA-A1 as targetingelement and three PD-L1 molecules as an effector element, according toone working example of the present disclosure.

FIG. 20A and FIG. 20B respectively show the mTOR inhibition and T-cellproliferation assay of sirolimus and sirolimus derivative compounds,according to one working example of the present disclosure.

FIG. 21A shows the staining analysis of the S1P1 receptor-expressinghuman B cells; FIG. 21B shows transwell migration assay of fingolimodupon the conjugation to peptide core through linking arms, according toone working example of the present disclosure.

FIG. 22A shows the SDS-PAGE analysis of purified recombinant 2-chain(CTLA-4)-IgG1.Fc-(scFv α HLA-A1) fusion protein; FIG. 22B and FIG. 22Crespectively show the ELISA analysis of purified recombinant 2-chain(CTLA-4)-IgG1.Fc-(scFv α HLA-A1) fusion protein with the scFv specificfor CTLA-4 and with human HLA-A1, according to one working example ofthe present disclosure.

FIG. 23A shows the SDS-PAGE analysis of purified recombinant 2-chain(PD-L1)-IgG4.Fc-(scFv α HLA-A1) fusion protein; FIGS. 23B to 23Drespectively show the ELISA analysis of purified recombinant 2-chain(PD-L1)-IgG4.Fc-(scFv α HLA-A1) fusion protein with the mAb specific forPD-L1, human PD-1, and human HLA-A1, according to one working example ofthe present disclosure.

In accordance with common practice, the various describedfeatures/elements are not drawn to scale but instead are drawn to bestillustrate specific features/elements relevant to the present invention.Also, like reference numerals and designations in the various drawingsare used to indicate like elements/parts, where possible.

DETAILED DESCRIPTION OF THE INVENTION

The detailed description provided below in connection with the appendeddrawings is intended as a description of the present examples and is notintended to represent the only forms in which the present example may beconstructed or utilized. The description sets forth the functions of theexample and the sequence of steps for constructing and operating theexample. However, the same or equivalent functions and sequences may beaccomplished by different examples.

For convenience, certain terms employed in the specification, examplesand appended claims are collected here. Unless otherwise defined herein,scientific and technical terminologies employed in the presentdisclosure shall have the meanings that are commonly understood and usedby one of ordinary skill in the art.

Unless otherwise required by context, it will be understood thatsingular terms shall include plural forms of the same and plural termsshall include the singular. Specifically, as used herein and in theclaims, the singular forms “a” and “an” include the plural referenceunless the context clearly indicated otherwise. Also, as used herein andin the claims, the terms “at least one” and “one or more” have the samemeaning and include one, two, three, or more. Furthermore, the phrases“at least one of A, B, and C”, “at least one of A, B, or C” and “atleast one of A, B and/or C,” as use throughout this specification andthe appended claims, are intended to cover A alone, B alone, C alone, Aand B together, B and C together, A and C together, as well as A, B, andC together.

Notwithstanding that the numerical ranges and parameters setting forththe broad scope of the invention are approximations, the numericalvalues set forth in the specific examples are reported as precisely aspossible. Any numerical value, however, inherently contains certainerrors necessarily resulting from the standard deviation found in therespective testing measurements. Also, as used herein, the term “about”generally means within 10%, 5%, 1%, or 0.5% of a given value or range.Alternatively, the term “about” means within an acceptable standarderror of the mean when considered by one of ordinary skill in the art.Other than in the operating/working examples, or unless otherwiseexpressly specified, all of the numerical ranges, amounts, values andpercentages such as those for quantities of materials, durations oftimes, temperatures, operating conditions, ratios of amounts, and thelikes thereof disclosed herein should be understood as modified in allinstances by the term “about.” Accordingly, unless indicated to thecontrary, the numerical parameters set forth in the present disclosureand attached claims are approximations that can vary as desired. At thevery least, each numerical parameter should at least be construed inlight of the number of reported significant digits and by applyingordinary rounding techniques. Ranges can be expressed herein as from oneendpoint to another endpoint or between two endpoints. All rangesdisclosed herein are inclusive of the endpoints, unless specifiedotherwise.

This present disclosure pertains generally to molecular constructs, inwhich each molecular construct comprises a targeting element (T) and aneffector element (E), and these molecular constructs are sometimesreferred to as “T-E molecules”, “T-E pharmaceuticals” or “T-E drugs” inthis document.

As used herein, the term “targeting element” refers to the portion of amolecular construct that directly or indirectly binds to a target ofinterest (e.g., a receptor on a cell surface or a protein in a tissue)thereby facilitates the transportation of the present molecularconstruct into the interested target. In some example, the targetingelement may direct the molecular construct to the proximity of thetarget cell. In other cases, the targeting element specifically binds toa molecule present on the target cell surface or to a second moleculethat specifically binds a molecule present on the cell surface. In somecases, the targeting element may be internalized along with the presentmolecular construct once it is bound to the interested target, hence isrelocated into the cytosol of the target cell. A targeting element maybe an antibody or a ligand for a cell surface receptor, or it may be amolecule that binds such antibody or ligand, thereby indirectlytargeting the present molecular construct to the target site (e.g., thesurface of the cell of choice). The localization of the effector(therapeutic agent) in the diseased site will be enhanced or favoredwith the present molecular constructs as compared to the therapeuticwithout a targeting function. The localization is a matter of degree orrelative proportion; it is not meant for absolute or total localizationof the effector to the diseased site.

According to the present invention, the term “effector element” refersto the portion of a molecular construct that elicits a biologicalactivity (e.g., inducing immune responses, exerting cytotoxic effectsand the like) or other functional activity (e.g., recruiting otherhapten tagged therapeutic molecules), once the molecular construct isdirected to its target site. The “effect” can be therapeutic ordiagnostic. The effector elements encompass those that bind to cellsand/or extracellular immunoregulatory factors. The effector elementcomprises agents such as proteins, nucleic acids, lipids, carbohydrates,glycopeptides, drug moieties (both small molecule drug and biologics),compounds, elements, and isotopes, and fragments thereof.

Although the terms, first, second, third, etc., may be used herein todescribe various elements, components, regions, and/or sections, theseelements (as well as components, regions, and/or sections) are not to belimited by these terms. Also, the use of such ordinal numbers does notimply a sequence or order unless clearly indicated by the context.Rather, these terms are simply used to distinguish one element fromanother.

Thus, a first element, discussed below, could be termed a second elementwithout departing from the teachings of the exemplary embodiments.

Here, the terms “link,” “couple,” and “conjugates” are usedinterchangeably to refer to any means of connecting two componentseither via direct linkage or via indirect linkage between twocomponents.

The term “polypeptide” as used herein refers to a polymer having atleast two amino acid residues. Typically, the polypeptide comprisesamino acid residues ranging in length from 2 to about 200 residues;preferably, 2 to 50 residues. Where an amino acid sequence is providedherein, L-, D-, or beta amino acid versions of the sequence are alsocontemplated. Polypeptides also include amino acid polymers in which oneor more amino acid residues are an artificial chemical analogue of acorresponding naturally occurring amino acid, as well as to naturallyoccurring amino acid polymers. In addition, the term applies to aminoacids joined by a peptide linkage or by other, “modified linkages,”e.g., where the peptide bond is replaced by an α-ester, a β-ester, athioamide, phosphoramide, carbomate, hydroxylate, and the like.

In certain embodiments, conservative substitutions of the amino acidscomprising any of the sequences described herein are contemplated. Invarious embodiments, one, two, three, four, or five different residuesare substituted. The term “conservative substitution” is used to reflectamino acid substitutions that do not substantially alter the activity(e.g., biological or functional activity and/or specificity) of themolecule. Typically, conservative amino acid substitutions involvesubstitution one amino acid for another amino acid with similar chemicalproperties (e.g., charge or hydrophobicity). Certain conservativesubstitutions include “analog substitutions” where a standard amino acidis replaced by a non-standard (e.g., rare, synthetic, etc.) amino aciddiffering minimally from the parental residue. Amino acid analogs areconsidered to be derived synthetically from the standard amino acidswithout sufficient change to the structure of the parent, are isomers,or are metabolite precursors.

In certain embodiments, polypeptides comprising at least 80%, preferablyat least 85% or 90%, and more preferably at least 95% or 98% sequenceidentity with any of the sequences described herein are alsocontemplated.

“Percentage (%) amino acid sequence identity” with respect to thepolypeptide sequences identified herein is defined as the percentage ofpolypeptide residues in a candidate sequence that are identical with theamino acid residues in the specific polypeptide sequence, after aligningthe sequences and introducing gaps, if necessary, to achieve the maximumpercent sequence identity, and not considering any conservativesubstitutions as part of the sequence identity. Alignment for purposesof determining percentage sequence identity can be achieved in variousways that are within the skill in the art, for instance, using publiclyavailable computer software such as BLAST, BLAST-2, ALIGN or Megalign(DNASTAR) software. Those skilled in the art can determine appropriateparameters for measuring alignment, including any algorithms needed toachieve maximal alignment over the full length of the sequences beingcompared. For purposes herein, sequence comparison between twopolypeptide sequences was carried out by computer program Blastp(protein-protein BLAST) provided online by Nation Center forBiotechnology Information (NCBI). The percentage amino acid sequenceidentity of a given polypeptide sequence A to a given polypeptidesequence B (which can alternatively be phrased as a given polypeptidesequence A that has a certain % amino acid sequence identity to a givenpolypeptide sequence B) is calculated by the formula as follows:

$\frac{X}{Y} \times 100\%$where X is the number of amino acid residues scored as identical matchesby the sequence alignment program BLAST in that program's alignment of Aand B, and where Y is the total number of amino acid residues in A or B,whichever is shorter.

The term “PEGylated amino acid” as used herein refers to a polyethyleneglycol (PEG) chain with one amino group and one carboxyl group.Generally, the PEGylated amino acid has the formula ofNH₂—(CH₂CH₂O)_(n)—COOH. In the present disclosure, the value of n rangesfrom 1 to 20; preferably, ranging from 2 to 12.

As used herein, the term “terminus” with respect to a polypeptide refersto an amino acid residue at the N- or C-end of the polypeptide. Withregard to a polymer, the term “terminus” refers to a constitutional unitof the polymer (e.g., the polyethylene glycol of the present disclosure)that is positioned at the end of the polymeric backbone. In the presentspecification and claims, the term “free terminus” is used to mean theterminal amino acid residue or constitutional unit is not chemicallybound to any other molecular.

The term “antigen” or “Ag” as used herein is defined as a molecule thatelicits an immune response. This immune response may involve asecretory, humoral, and/or cellular antigen-specific response. In thepresent disclosure, the term “antigen” can be any of a protein, apolypeptide (including mutants or biologically active fragmentsthereof), a polysaccharide, a glycoprotein, a glycolipid, a nucleicacid, or a combination thereof.

In the present specification and claims, the term “antibody” is used inthe broadest sense and covers fully assembled antibodies, antibodyfragments that bind with antigens, such as antigen-binding fragment(Fab/Fab′), F(ab′)₂ fragment (having two antigen-binding Fab portionslinked together by disulfide bonds), variable fragment (Fv), singlechain variable fragment (scFv), bi-specific single-chain variablefragment (bi-scFv), nanobodies, unibodies and diabodies. “Antibodyfragments” comprise a portion of an intact antibody, preferably theantigen-binding region or variable region of the intact antibody.Typically, an “antibody” refers to a protein consisting of one or morepolypeptides substantially encoded by immunoglobulin genes or fragmentsof immunoglobulin genes. The well-known immunoglobulin genes include thekappa, lambda, alpha, gamma, delta, epsilon, and mu constant regiongenes, as well as myriad immunoglobulin variable region genes. Lightchains are classified as either kappa or lambda. Heavy chains areclassified as gamma, mu, alpha, delta, or epsilon, which in turn definethe immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Atypical immunoglobulin (antibody) structural unit is known to comprise atetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, with each pair having one “light” chain (about 25kDa) and one “heavy” chain (about 50-70 kDa). The N-terminus of eachchain defines a variable region of about 100 to 110 or more amino acidsprimarily responsible for antigen recognition. The terms variable lightchain (V_(L)) and variable heavy chain (V_(H)) refer to these light andheavy chains, respectively. According to embodiments of the presentdisclosure, the antibody fragment can be produced by modifying thenature antibody or by de novo synthesis using recombinant DNAmethodologies. In certain embodiments of the present disclosure, theantibody and/or antibody fragment can be bispecific, and can be invarious configurations. For example, bispecific antibodies may comprisetwo different antigen binding sites (variable regions). In variousembodiments, bispecific antibodies can be produced by hybridomatechnique or recombinant DNA technique. In certain embodiments,bispecific antibodies have binding specificities for at least twodifferent epitopes.

The term “specifically binds” as used herein, refers to the ability ofan antibody or an antigen-binding fragment thereof, to bind to anantigen with a dissociation constant (Kd) of no more than about 1×10⁻⁶M, 1×10⁻⁷ M, 1×10⁻⁸ M, 1×10⁻⁹ M, 1×10⁻¹0 M, 1×10⁻¹¹ M, 1×10⁻¹² M, and/orto bind to an antigen with an affinity that is at least two-foldsgreater than its affinity to a nonspecific antigen.

The term “treatment” as used herein includes preventative (e.g.,prophylactic), curative or palliative treatment; and “treating” as usedherein also includes preventative (e.g., prophylactic), curative orpalliative treatment. In particular, the term “treating” as used hereinrefers to the application or administration of the present molecularconstruct or a pharmaceutical composition comprising the same to asubject, who has a medical condition a symptom associated with themedical condition, a disease or disorder secondary to the medicalcondition, or a predisposition toward the medical condition, with thepurpose to partially or completely alleviate, ameliorate, relieve, delayonset of, inhibit progression of, reduce severity of, and/or reduceincidence of one or more symptoms or features of said particulardisease, disorder, and/or condition. Treatment may be administered to asubject who does not exhibit signs of a disease, disorder, and/orcondition, and/or to a subject who exhibits only early signs of adisease, disorder and/or condition, for the purpose of decreasing therisk of developing pathology associated with the disease, disorderand/or condition.

The term “effective amount” as used herein refers to the quantity of thepresent molecular construct that is sufficient to yield a desiredtherapeutic response. An effective amount of an agent is not required tocure a disease or condition but will provide a treatment for a diseaseor condition such that the onset of the disease or condition is delayed,hindered or prevented, or the disease or condition symptoms areameliorated. The effective amount may be divided into one, two, or moredoses in a suitable form to be administered at one, two or more timesthroughout a designated time period. The specific effective orsufficient amount will vary with such factors as particular conditionbeing treated, the physical condition of the patient (e.g., thepatient's body mass, age, or gender), the type of subject being treated,the duration of the treatment, the nature of concurrent therapy (ifany), and the specific formulations employed and the structure of thecompounds or its derivatives. Effective amount may be expressed, forexample, as the total mass of active component (e.g., in grams,milligrams or micrograms) or a ratio of mass of active component to bodymass, e.g., as milligrams per kilogram (mg/kg).

The terms “application” and “administration” are used interchangeablyherein to mean the application of a molecular construct or apharmaceutical composition of the present invention to a subject in needof a treatment thereof.

The terms “subject” and “patient” are used interchangeably herein andare intended to mean an animal including the human species that istreatable by the molecular construct, pharmaceutical composition, and/ormethod of the present invention. The term “subject” or “patient”intended to refer to both the male and female gender unless one genderis specifically indicated. Accordingly, the term “subject” or “patient”comprises any mammal, which may benefit from the treatment method of thepresent disclosure.

Examples of a “subject” or “patient” include, but are not limited to, ahuman, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat,bird and fowl. In an exemplary embodiment, the patient is a human. Theterm “mammal” refers to all members of the class Mammalia, includinghumans, primates, domestic and farm animals, such as rabbit, pig, sheep,and cattle; as well as zoo, sports or pet animals; and rodents, such asmouse and rat. The term “non-human mammal” refers to all members of theclass Mammalis except human.

Throughout the present disclosure, the term “transplantation rejection”refers to the acute or chronic rejection of cells, tissue or solid organallografts or xenografts of, among the others, pancreatic islets, stemcells, bone marrow, skin, muscle, corneal tissue, neuronal tissue,heart, lung, combined heart-lung, kidney, liver, bowel, pancreas,trachea or esophagus, or graft-versus-host diseases.

As used herein, the term “donor transplant” refers to a population ofcells, or a tissue or an organ that is to be moved from one body toanother or from a donor site to another location on the subject's ownbody, for the purpose of replacing the recipient's damaged or absenttissue or organ.

The present disclosure is based, at least on the construction of the T-Epharmaceuticals that can be delivered to target cells, target tissues ororgans at increased proportions relative to the blood circulation,lymphoid system, and other cells, tissues or organs. When this isachieved, the therapeutic effect of the pharmaceuticals is increased,while the scope and severity of the side effects and toxicity isdecreased. It is also possible that a therapeutic effector isadministered at a lower dosage in the form of a T-E molecule, than in aform without a targeting component. Therefore, the therapeutic effectorcan be administered at lower dosages without losing potency, whilelowering side effects and toxicity.

Diseases that can Benefit from Better Drug Targeting

Drugs used for many diseases can be improved for better efficacy andsafety, if they can be targeted to the disease sites, i.e., if they canbe localized or partitioned to the disease sites more favorably than thenormal tissues or organs. Certain antibody drugs, which targetinfectious microorganisms or their toxic products, can be improved, ifthey are empowered with the ability to recruit immunocytes, whichphagocytose and clear the antibody-bound particles. Following areprimary examples of diseases, in which drugs can be improved if they canbe preferentially distributed to the disease sites or cells or if theycan recruit phagocytic immunocytes.

Examples of transplantation-related diseases/conditions include, but arenot limited to, organ transplant rejection (including, chronic, acute,subacute, and hyperacute rejection) and graft-versus-host disease(GvHD).

Transplantation is the act of transferring cells, tissues, or organsfrom one body to another or from a donor site to another location of theperson's own body. The malfunction of an organ system can be correctedwith transplantation of an organ from a donor. However, the donortransplants (such as the transplanted organ, tissue or cells),especially in allografts or xenografts, are recognized as foreign agentsby the recipient's immune system, thereby causing the rejection oftransplanted organs, tissues or cells.

Although there are many antigens involved in the rejection ofgenetically disparate tissues, those responsible for the most vigorousallograft rejection reactions are the major histocompatibility complex(MHC). In humans, the MHC is called the human leukocyte antigen (HLA)system and is located on the short arm of chromosome 6, near thecomplement genes. The most studied HLA genes are the nine classical MHCgenes: HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1,HLA-DRA, and HLA-DRB1. In humans, the MHC gene cluster is divided intothree regions: classes I, II, and III. The A, B and C genes belong toMHC class I, whereas the six D genes belong to class II.

The MHC expression is codominant, meaning that both set of inheritedalleles are expressed equally on the cell surface. Furthermore, the setof MHC alleles are inherited as haplotypes; hence, a heterozygousindividual will have two MHC haplotypes, one from the paternalchromosome and the other from maternal chromosome. Each person carriestwo alleles of each of the three class-I genes, (HLA-A, HLA-B andHLA-C), and hence can express six different types of MHC-I. In theclass-II locus, each person inherits a pair of HLA-DP genes (DPA1 andDPB1), a couple of genes HLA-DQ (DQA1 and DQB1), one gene HLA-DRα(DRA1), and one or more genes HLA-DRβ (DRB1 and DRB3, -4 or -5);accordingly, one heterozygous individual can inherit six or eightfunctioning class-II alleles, three or more from each parent. The MHCgenes are highly polymorphic; many different alleles exist in thedifferent individuals inside a population.

Both MHC class I and MHC class II proteins play a role in transplantrejection. MHC class I are expressed on all nucleated cells; and theseclass I molecules are responsible for presenting antigenic peptides fromwithin the cell (e.g., self-antigens, antigens from the intracellularviruses, and tumor-associated antigens) to T cells having CD8 receptors,such as alloreactive killer T cells (also known as cytotoxic Tlymphocytes (CTLs). Once the T cell receptors (TCRs) of CTLs recognizethe transplanted tissue's MHC class I molecules, the CTLs trigger thetarget cell's programmed cell death by apoptosis. On the other hand, MHCclass II normally occurs only on the professional antigen-presentingcells (APCs), such as dendritic cells, activated macrophages, and Bcells. The MHC class II present extracellular antigens to CD4 T cells.When memory helper T cells' CD4 receptors bind to the MHC class IImolecules expressed on the surfaces of the target cells of the grafttissue, the memory helper T cells' TCRs recognize their target antigen,and subsequently produces clones that, as effector cells, secrete immunesignaling molecules (cytokines) in approximately the cytokine balancethat had prevailed at the memory helper T cell's priming to memorize theantigen. As the priming event in this instance occurred amidinflammation, the immune memory is pro-inflammatory.

Graft-versus-host disease is a medical complication following thereceipt of donor tissue from a genetically different person. GvHD iscommonly associated with stem cell or bone marrow transplant but theterm also applies to other forms of tissue graft. Immune cells (whiteblood cells) in the donated tissue (the graft) recognize the recipient(the host) as “foreign;” and then the transplanted immune cells attackthe host's body cells.

The T-E molecular design of this invention can be applied for preparingmolecular constructs for preventing the rejection of the donortransplant(s).

In the present molecular constructs, the targeting elements are scFv ofantibodies specific for an HLA A, B, or C allotype expressed by cells ofthe donor transplant and not by cells of the patient receiving thetransplant. Since there are six genes in the haplotypes of HLA A, B, andC, it is not difficult to find one gene with different allotypes betweenthe donor and the recipient. Many antibodies against HLA allotypes arealready available. For example, antibodies specific for HLA A2 and B27are well known. An antibody specific for Cw1 antigen (correspondingallele: C*01:02) was made. Some antibodies bind to determinants sharedby several allotypes, for example, one antibody binds to A11 and A24 andanother one to A11, A25, A26, and A66. A panel of antibodies binding tovarious HLA allotypes may be established by isolating HLA A, B, and Callotype-specific B cells from the peripheral blood of patientsreceiving transplants and cloning the VH and VL sequences of those Bcells by RT-PCR. Similar procedures have been established in preparingantigen-specific human monoclonal antibodies for various viral antigens.A molecular construct with an scFv specific for an HLA allotype can thenbe chosen for a patient who has received a transplant with a particularhaplotype.

The effector elements can be chosen from (1) the ectodomain orextracellular domain of immune checkpoint proteins, such as CTLA-4 andPD-L1, which can inhibit on-going immune activation, (2) scFv ofantibodies specific for CD25, which is expressed by activated T cells,or (3) small molecular immunosuppressive drugs, sirolimus (rapamycin),everolimus, and tacrolimus (FK-506), which have been used broadly forthe prevention of transplantation rejection. Sirolimus and everolimus,which inhibit mTOR (mammalian target of rapamycin), and tacrolimus,which inhibits calcineurin, are powerful inhibitors of T cell activity.Fingolimod and derivatives thereof (e.g., fingolimod phosphate) are alsoexamples of suitable immunosuppressants. Anti-CD25, fingolimod,sirolimus, everolimus and tacrolimus, each have a range of its seriousside effects due to their potent immunosuppressive effects. It isdesirable to shuffle increased proportions of the drug to the transplantand decreased proportions in other parts of the body, especially theblood and lymphoid system.

Sirolimus (m.w. 914.172 daltons) and tacrolimus (m.w. 804.018 daltons)are suitable for the present application, because in most applications,sirolimus or everolimus is used at approximately 2-10 mg per day andtacrolimus is used at approximately 5-15 mg per day. Theimmunosuppressive drugs cyclosporine (m.w. 1,202.61 daltons) andmycophenolic acid (m.w. 320.34 daltons), which are also used for theprevention of rejection of transplants, are not suitable for use herein,because cyclosporin is used at approximately 150-1,000 mg per day, andmycophenolic acid is used at approximately 800-1,500 mg per day. For amolecular construct with two scFvs as targeting elements and tensirolimus molecules as effector elements, the weight of the scFv (m.w.25,000 daltons) is about 6 times of the weight of sirolimus. Thus, foradministering 5 mg of sirolimus, it requires 30 mg of scFv, which isfeasible. Because the administered sirolimus will be carried to thetransplant, a less amount will be required than if the drug isadministered without targeting to the transplant.

Since sirolimus, everolimus, and tacrolimus, act on intracellulartargets of T cells, they are linked to the multi-arm linker-unit via areversible bond, which is cleaved off the linker by hydrolysis or bycleavage by tissue proteases present in the targeted tissue. Since themolecular constructs of the present invention are administeredintravenously, they can reach the target site in a fast kinetics andhydrolysis en route is not a major problem. Sirolimus, everolimus, andtacrolimus molecules have been synthesized de novo in organic chemistrylaboratories. Various conjugating groups, such as sulfhydryl and aminegroups can be incorporated to side chains that do not interfere the drugmolecules to inhibit their targets. Furthermore, it is not a concernthat the linkage to the linker-unit blocks the activity of fingolimod,sirolimus, everolimus and tacrolimus. The immunosuppressors regainactivity after they are released. According to embodiments of thepresent disclosure, some T-E molecules in single linker-units or jointlinkers configuration incorporate scFvs specific for an allogeneic HLAA, B, or C antigen (not present in the treated patient) as targetingelements and, sirolimus, everolimus, tacrolimus or scFv specific forCD25 as effector elements.

Fingolimod and fingolimod phosphate can provide as a good candidate forinhibiting the rejection reaction in transplantation. In clinical trialsof fingolimod for kidney transplantation, it was not found to be betterthan other established, standard care. However, if increasedconcentration of fingolimod can be reached in the transplanted organ,effective immune suppression against host immune response may beachieved in the transplanted organ.

The strategies of targeting of immunosuppressive agents to thetransplanted organs may be applied to the treatment of graft-versus-hostdiseases (GvHD). In patients who receive stem cells, bone marrowtransplants, or even tissues or blood transfusions, the immune cells inthe transplants recognize the host cells as foreign and mount immuneresponse against the host cells, causing severe damages in the liver,the skin, the mucosa, the gastrointestinal tracts, and other organs andtissues of the recipient.

Immunosuppressive agents, such as sirolimus, everolimus, tacrolimus,fingolimod, or fingolimod phosphate, may be carried to the cellsexpressing an HLA allele expressed on the graft leukocytes. Thesetargeted cells include T cells, which are mainly responsible for thecytolytic activities observed in GvHD. When the T cells from the graftare inhibited, the GvHD should improve.

PART I Multi-Arm Linkers for Treating Specific Diseases

In various embodiments, the present disclosure provides a multi-armlinker unit for treating transplantation rejection in a subject.According to various embodiments of the present disclosure, the linkerunit comprises a center core, a plurality of linking arms, a pluralityof first elements, and optionally, a coupling arm and a second element.

The center core can be a peptide core having a pre-defined number ofamine (—NH₂) groups, before being linked with the linking arms. Forexample, the peptide core may have two or more lysine (K) resides havingan amine (—NH₂) group at the side chain.

In the following sections, the structure of the peptide core suitablefor use herein is disclosed, followed by a description regarding thefunctional elements suitable for use to construct the present multi-armlinker, and the uses of such multi-arm linker.

The first aspect of the present disclosure pertains to a linker unitthat comprises, (1) a center core that comprises 2-15 lysine (K)residues, and (2) 2-15 linking arms respectively linked to the Kresidues of the center core. The present center core is characterized inhaving or being linked with an azide group, an alkyne group, a tetrazinegroup, or a strained alkyne group at its N- or C-terminus.

In the preparation of the present linker unit, a PEG chain having aN-hydroxysuccinimidyl (NHS) group at one terminus and a functional group(e.g., an NHS, a maleimide, an azide, an alkyne, a tetrazine, or astrained alkyne group) at the other terminus is linked to the K residueof the center core by forming an amide bond between the NHS group of thePEG chain and the amine group of the K residue. In the presentdisclosure, the PEG chain linked to the K residue is referred to as alinking arm, which has a functional group at the free-terminus thereof.

According to the embodiments of the present disclosure, the center coreis a polypeptide that has 8-120 amino acid residues in length andcomprises 2 to 15 lysine (K) residues, in which each K residue and thenext K residue are separated by a filler sequence.

According to embodiments of the present disclosure, the filler sequencecomprises glycine (G) and serine (S) residues; preferably, the fillersequence consists of 2-15 residues selected from G, S, and a combinationthereof. For example, the filler sequence can be,

GS, GGS, GSG, (SEQ ID NO: 1) GGGS, (SEQ ID NO: 2) GSGS, (SEQ ID NO: 3)GGSG, (SEQ ID NO: 4) GSGGS, (SEQ ID NO: 5) SGGSG, (SEQ ID NO: 6) GGGGS,(SEQ ID NO: 7) GGSGGS, (SEQ ID NO: 8) GGSGGSG, (SEQ ID NO: 9) SGSGGSGS,(SEQ ID NO: 10) GSGGSGSGS, (SEQ ID NO: 11) SGGSGGSGSG, (SEQ ID NO: 12)GGSGGSGGSGS, (SEQ ID NO: 13) SGGSGGSGSGGS, (SEQ ID NO: 14)GGGGSGGSGGGGS, (SEQ ID NO: 15) GGGSGSGSGSGGGS, or (SEQ ID NO: 16)SGSGGGGGSGGSGSG.

The filler sequence placed between two lysine residues may be variationsof glycine and serine residues in somewhat random sequences and/orlengths. Longer fillers may be used for a polypeptide with fewer lysineresidues, and shorter fillers for a polypeptide with more lysineresidues. Hydrophilic amino acid residues, such as aspartic acid andhistidine, may be inserted into the filler sequences together withglycine and serine. As alternatives for filler sequences made up withglycine and serine residues, filler sequences may also be adopted fromflexible, soluble loops in common human serum proteins, such as albuminand immunoglobulins.

Basically, the filler sequences between lysine residues cover peptideswith glycine and serine residues. However, they can alternatively bepeptides composed of amino acids excluding one with amine group in itsside chain. Those amino acids are predominantly, but not necessarilyentirely hydrophilic amino acids. The amino acids are not necessarilynaturally occurring amino acids.

According to certain preferred embodiments of the present disclosure,the center core comprises 2-15 units of the sequence of G₁₋₅SK.Alternatively, the polypeptide comprises the sequence of (GSK)₂₋₁₅; thatis, the polypeptide comprises at least two consecutive units of thesequence of GSK. For example, the present center core may comprises theamino acid sequence of the following,

(SEQ ID NO: 17) Ac-CGGSGGSGGSKGSGSK, (SEQ ID NO: 18)Ac-CGGSGGSGGSKGSGSKGSK, or (SEQ ID NO: 19)Ac-CGSKGSKGSKGSKGSKGSKGSKGSKGSKGSK,in which Ac represents the acetyl group.

According to certain embodiments of the present disclosure, the centercore is a polypeptide that comprises the sequence of (X_(aa)-K)_(n), inwhich X_(aa) is a PEGylated amino acid having 2 to 12 repeats ofethylene glycol (EG) unit, and n is an integral from 2 to 15.

As would be appreciated, the lysine residue of the present center coremay be substituted with an amino acid, which side chain contains anamine group. For example, an α-amino acid with (CH₂-)nNH₂ side chain,where n=1-3 or 5; an α-amino acid with (CH(OH)-)nCH₂—NH₂ side chain,where n=1-5; an α-amino acid with (CH₂—CH(OH)-)nCH₂—NH₂ side chain,where n=1-3; an α-amino acid with (CH₂—CH₂—O-)nCH₂—NH₂ side chain, wheren=1-2. These amino acids are not necessarily naturally occurring aminoacids.

As described above, the present center core is characterized in havingor being linked with an azide group, an alkyne group, a tetrazine group,or a strained alkyne group at its N- or C-terminus. According to someembodiments of the present disclosure, the present center corecomprises, at its N- or C-terminus, an amino acid residue having anazide group or an alkyne group. The amino acid residue having an azidegroup can be, L-azidohomoalanine (AHA), 4-azido-L-phenylalanine,4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine,4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine,5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine. For example,the present center core may have the sequence of,

Ac-(GSK)₂₋₇-(G₂₋₄S)₁₋₈-A^(AH),

Ac-A^(AH)-(SG₂₋₄)₁₋₈-(GSK)₂₋₇,

Ac-A^(AH)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C,

Ac—C—(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈-A^(AH)

Ac—K-(Xaa₂₋₁₂-K)₂₋₄-Xaa₂₁₂-A^(AH),

Ac-A^(AH)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₂₋₄,

Ac-A^(AH)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C, or

Ac—C-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-A^(AH),

in which Xaa is a PEGylated amino acid having specified repeats of EGunit, Ac represents the acetyl group, and A^(AH) represents the AHAresidue.

Exemplary amino acid having an alkyne group includes, but is not limitedto, L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), orbeta-homopropargylglycine (β-HPG). In this case, the present center coremay have the sequence of,

Ac-(GSK)₂₋₇-(G₂₋₄S)₁₋₈-G^(HP),

Ac-G^(HP)-(SG₂₋₄)₁₋₈-(GSK)₂₋₇,

Ac-G^(HP)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C,

Ac—C—(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈-G^(HP),

Ac—K-(Xaa₂₋₁₂-K)₂₋₄-Xaa₂₋₁₂-G^(HP)

Ac-G^(HP)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₂₋₄,

Ac-G^(HP)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C, or

Ac—C-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-G^(HP),

in which Xaa is a PEGylated amino acid having specified repeats of EGunit, Ac represents the acetyl group, and G^(HP) represents the HPGresidue.

It is noted that many of the amino acids containing an azide or alkynegroup in their side chains and PEGylated amino acids are availablecommercially in t-boc (tert-butyloxycarbonyl)- or Fmoc(9-fluorenylmethyloxycarbonyl)-protected forms, which are readilyapplicable in solid-phase peptide synthesis.

According to some working examples of the present disclosure, the centercore may comprise the sequence of,

(SEQ ID NO: 20) Ac-G^(HP)GGSGGSGGSKGSGSK, (SEQ ID NO: 21)Ac-G^(HP)GGSGGSGGSKGSGSKGSK, (SEQ ID NO: 22)Ac-A^(AH)GGSGGSGGSKGSGSKGSK, (SEQ ID NO: 23)Ac-G^(HP)GGSGGSGGSKGSGSKGSGSC, (SEQ ID NO: 24)Ac-C-Xaa₂-K-Xaa₂-K-Xaa₂-K, or (SEQ ID NO: 25)Ac-C-Xaa₆-K-Xaa₆-K-Xaa₆-K-Xaa₆-K-Xaa₆-K,in which Xaa is a PEGylated amino acid having specified repeats of EGunit, Ac represents the acetyl group, A^(AH) represents the AHA residue,and G^(HP) represents the HPG residue.

Alternatively, the present center core is linked with a coupling arm,which has a functional group (e.g., an azide group, an alkyne group, atetrazine group, or a strained alkyne group) at the free-terminusthereof (that is, the terminus that is not linked to the center core).In these cases, the present center core comprises a cysteine residue atits N- or C-terminus. To prepare a linker unit linked with a couplingarm, a PEG chain having a maleimide group at one terminus and afunctional group at the other terminus is linked to the cysteine residueof the center core via thiol-maleimide reaction occurred between themaleimide group of the PEG chain and the thiol group of the cysteineresidue. In the present disclosure, the PEG chain linked to the cysteineresidue of the center core is referred to as the coupling arm, which hasa functional group at the free-terminus thereof.

As would be appreciated, the cysteine residue of the present center coremay be substituted with an amino acid, which side chain contains asulfhydryl group. For example, an α-amino acid with (CH(OH)-)nCH₂—SHside chain, where n=1-5; an α-amino acid with (CH₂—CH(OH)-)nCH₂—SH sidechain, where n=1-3; an α-amino acid with (CH₂—CH₂—O-)nCH₂—SH side chain,where n=1-2. The amino acid is not necessarily naturally occurring aminoacids. The cysteine residue need not be placed at the N- or C-terminalof the peptide core. For example, the cysteine residue can be placed inthe middle of the peptide, so that the lysine residues are distributedon two sides of the cysteine residue.

Preferably, the coupling arm has a tetrazine group or a strained alkynegroup (e.g., a cyclooctene or cyclooctyne group) at the free-terminusthereof. These coupling arms have 2-12 EG units. According to theembodiments of the present disclosure, the tetrazine group is1,2,3,4-tetrazine, 1,2,3,5-tetrazine, 1,2,4,5-tetrazine, or derivativesthereof. The strained alkyne group may be a cyclooctene or a cyclooctynegroup. According to the working examples of the present disclosure, thecyclooctene group is a trans-cyclooctene (TCO) group; example ofcyclooctyne group includes, but is not limited to, dibenzocyclooctyne(DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BCN), anddibenzocyclooctyne (DICO). According to some embodiments of the presentdisclosure, the tetrazine group is 6-methyl-tetrazine.

Example of the present center core configured to be linked with thecoupling arm includes, but is not limited to,

Ac-(GSK)₂₋₇-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-tetrazine,

Ac-(GSK)₂₇-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-strained alkyne,

Ac-K-(Xaa₂₋₁₂-K)₂₋₄-Xaa₂₋₁₂-C-Xaa₂₋₁₂-tetrazine,

Ac-K-(Xaa₂₋₁₂-K)₂₋₄-Xaa₂₋₁₂-C-Xaa₂₋₁₂-strained alkyne,

Tetrazine-Xaa₂₋₁₂-C(Ac)-(SG₂₋₄)₁₋₈-(GSK)₂₋₇,

Strained alkyne-Xaa₂₋₁₂-C(Ac)-(SG₂₋₄)₁₋₈-(GSK)₂₋₇,

Tetrazine-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₂₋₄, and

Strained alkyne-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₂₋₄.

Alternatively, the center core has an azide or alkyne group at oneterminus and a coupling arm with tetrazine or strained alkyne group atthe other terminus. Examples are the following:

Ac-A^(AH)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-tetrazine,

Ac-A^(AH)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-strained alkyne,

Tetrazine-Xaa₂₋₁₂-C(Ac)—(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈-A^(AH),

Strained alkyne-Xaa₂₋₁₂-C(Ac)—(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈-A^(AH),

Ac-A^(AH)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C-Xaa₂₋₁₂-tetrazine,

Ac-A^(AH)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C-Xaa₂₋₁₂-strained alkyne,

Tetrazine-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂₋A^(AH),

Strained alkyne-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-A^(AH),

Ac-G^(HP)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-tetrazine,

Ac-G^(HP)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₋₈—C-Xaa₂₋₁₂-strained alkyne,

Tetrazine-Xaa₂₋₁₂-C(Ac)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G₂₋₄S)₁₈-G^(HP),

Strained alkyne-Xaa₂₋₁₂-C(AC)-(SG₂₋₄)₀₋₇-(GSK)₂₋₆-(G(G₂₋₄S)₁₋₈-G^(HP),

Ac-G^(HP)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C-Xaa₂₋₁₂-tetrazine,

Ac-G^(HP)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-C-Xaa₂₋₁₂-strained alkyne,

Tetrazine-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂₋G^(HP), and

Strained alkyne-Xaa₂₋₁₂-C(Ac)-Xaa₂₋₁₂-K-(Xaa₂₋₁₂-K)₁₋₃-Xaa₂₋₁₂-G^(HP).

The polypeptide may also be synthesized using recombinant technology byexpressing designed gene segments in bacterial or mammalian host cells.It is preferable to prepare the polypeptide as recombinant proteins ifthe core has high numbers of lysine residues with considerable lengths.As the length of a polypeptide increases, the number of errorsincreases, while the purity and/or the yield of the product decrease, ifsolid-phase synthesis was adopted. To produce a polypeptide in bacterialor mammalian host cells, a filler sequence ranges from a few amino acidresidues to 10-20 residues may be placed between two K residues.Further, since AHA and HPG are not natural amino acids encoded by thegenetic codes, the N-terminal or C-terminal residue for thoserecombinant polypeptides is cysteine. After the recombinant proteins areexpressed and purified, the terminal cysteine residue is then reactedwith short bifunctional cross-linkers, which have maleimide group at oneend, which reacts with SH group of cysteine residue, and alkyne, azide,tetrazine, or strained alkyne at the other end.

The synthesis of a polypeptide using PEGylated amino acids involvesfewer steps than that with regular amino acids such as glycine andserine resides. In addition, PEGylated amino acids with varying lengths(i.e., numbers of repeated ethylene glycol units) may be employed,offering flexibility for solubility and spacing between adjacent aminogroups of lysine residues. Other than PEGylated amino acids, the centercores may also be constructed to comprise artificial amino acids, suchas D-form amino acids, homo-amino acids, N-methyl amino acids, etc.Preferably, the PEGylated amino acids with varying lengths ofpolyethylene glycol (PEG) are used to construct the center core, becausethe PEG moieties contained in the amino acid molecules provideconformational flexibility and adequate spacing between conjugatinggroups, enhance aqueous solubility, and are generally weaklyimmunogenic. The synthesis of PEGylated amino acid-containing centercore is similar to the procedures for the synthesis of regularpolypeptides.

Optionally, for stability purpose, the present center core has an acetylgroup to block the amino group at its N-terminus.

As could be appreciated, the number of the linking arms linked to thecenter core is mainly determined by the number of lysine residescomprised in the center core. Since there are at least two lysineresidues comprised in the present center core, the present linker unitmay comprise a plurality of linking arms.

Reference is now made to FIG. 1A. As illustrated, the linker unit 10Acomprises a center core 11 a comprising one HPG (G^(HP)) residue andfour lysine (K) residues respectively separated by filler sequences(denoted by the dots throughout the drawings). The filler sequencesbetween the HPG residue and K residue or between any two K residues maycomprise the same or different amino acid sequences. In this example,four linking arms 20 a-20 d are linked to the lysine residues by formingan amide linkage between the NHS group and the amine group of the lysineresidue, respectively. As could be appreciated, certain featuresdiscussed above regarding the linker unit 10A or any other followinglinker units are common to other linker units disclosed herein, andhence some or all of these features are also applicable in the followingexamples, unless it is contradictory to the context of a specificembodiment. However, for the sake of brevity, these common features maynot be explicitly repeated below.

FIG. 1B provides a linker unit 10B according to another embodiment ofthe present disclosure. The center core 11 b comprises one cysteine (C)residue and six lysine (K) residues respectively separated by the fillersequences. In this example, the linker unit 10B comprises six linkingarms 20 a-20 f that are respectively linked to the lysine residues.According to the embodiments of the present disclosure, the linking armis a PEG chain having 2-20 repeats of EG units.

Unlike the linker unit 10A of FIG. 1A, the linker unit 1B furthercomprises a coupling arm 60. As discussed above, a PEG chain having amaleimide group at one end and a functional group at the other end isused to form the coupling arm 60. In this way, the coupling arm 60 islinked to the cysteine residue of the center core 11 b viathiol-maleimide reaction. In this example, the functional group at thefree terminus of the coupling arm 60 is a tetrazine group 72. Accordingto the embodiments of the present disclosure, the coupling arm is a PEGchain having 2-12 repeats of EG units.

When the release of effector elements at the targeted site is required,a cleavable bond can be installed in the linking arm. Such a bond iscleaved by acid/alkaline hydrolysis, reduction/oxidation, or enzymes.One embodiment of a class of cleavable PEG chains that can be used toform the coupling arm is NHS-PEG₂₋₂₀-S-S-maleimide, where S—S is adisulfide bond that can be slowly reduced, while the NHS group is usedfor conjugating with the amine group of the center core, thereby linkingthe PEG chain onto the center core. The maleimide group at the freeterminus of the linking arm may be substituted by an azide, alkyne,tetrazine, or strained alkyne group.

According to the embodiments of the present disclosure, the linking armlinked to the K residue of the center core has a functional group (i.e.,a maleimide, an NHS, an azide, an alkyne, a tetrazine, or a strainedalkyne group) at its free terminus. Preferably, when the free terminusof the linking arm is an azide, alkyne, or cyclooctyne group, then theamino acid residue at the N- or C-terminus of the center core is acysteine residue, and the free terminus of the coupling arm is atetrazine or cyclooctene group. Alternatively, when the free terminus ofthe linking arm is a tetrazine group or cyclooctene group, then theamino acid residue at the N- or C-terminus of the center core has anazide or alkyne group, or the amino acid residue at the N- or C-terminusof the center core is a cysteine residue, and the free terminus of thecoupling arm is an azide, the alkyne, or the cyclooctyne group.

As could be appreciated, the preferred linking arms for this inventionare PEG; however, applicable linking arms and coupling arms are notlimited to PEG chains. Peptides comprising glycine, serine and otheramino acid hydrophilic residues, and polysaccharides, and otherbiocompatible linear polymers, which are modified to contain NHS andmaleimide groups, can be used.

The length of the linking arms is important for several considerations.It should be long enough to allow flexibility of the linked scFv orother types of functional elements to reach targeted antigenic sites ontargeted cell surface without steric constraints; yet not long enough tocause intra-molecular and inter-molecular tangling of the linking armsand their linked scFv fragments or functional elements, or tounnecessarily increase the size of the whole molecular construct forhindering tissue penetration. Linking arms that are too long may alsofail to pull antigen molecules to form compacted clusters, if suchclusters are required to initiate signal-transducing process forapoptosis or other cellular effects. The optimal length of linking armsfor different types of combinations of targeted antigens and theirbinding agents may be determined by any skilled artisan in the relatedfield without undue experimentation. A linking arm ofNHS-(PEG)₁₂-Maleimide (approximately 500 Daltons) is preferred in anumber of molecular construct of this invention. A fully stretched(PEG)₁₂ has a length of 40-50 Å.

Depending on the functional group (i.e., a maleimide, an NHS, an azide,an alkyne, a tetrazine, or a strained alkyne group) present at the freeterminus of the linking arm, it is feasible to design a functionalelement (such as, a targeting element, an effector element, or anelement for improving the pharmacokinetic property) with a correspondingfunctional group, so that the functional element may linked to the freeterminus of the linking arm via any of the following chemical reactions,

(1) forming an amide bond therebetween: in this case, the linking armhas an NHS group at the free terminus, and the functional element has anamine group;

(2) the thiol-maleimide reaction: in this case, the linking arm has amaleimide group at the free terminus, and the functional element has anthiol group;

(3) the Copper(I)-catalyzed alkyne-azide cycloaddition reaction (CuAACreaction, or the “click” reaction for short): one of the free terminusof the linking arm and the functional element has an azide group, whilethe other has an alkyne group; the CuAAC reaction is exemplified inScheme 1;

(4) the inverse electron demand Diels-Alder (iEDDA) reaction: one of thefree terminus of the linking arm and the functional element has atetrazine group, while the other has a cyclooctene group; the iEDDAreaction is exemplified in Scheme 2; or

(5) the strained-promoted azide-alkyne click chemistry (SPAAC) reaction:one of the free terminus of the linking arm and the functional elementhas an azide group, while the other has an cyclooctyne group; the SPAACreaction is exemplified in Scheme 3.

The CuAAC reaction yields 1,5 di-substituted 1,2,3-triazole. Thereaction between alkyne and azide is very selective and there are noalkyne and azide groups in natural biomolecules. Furthermore, thereaction is quick and pH-insensitive. It has been suggested that insteadof using copper (I), such as cuprous bromide or cuprous iodide, forcatalyzing the click reaction, it is better to use a mixture of copper(II) and a reducing agent, such as sodium ascorbate to produce copper(I) in situ in the reaction mixture. Alternatively, the second elementcan be linked to the N- or C-terminus of the present center core via acopper-free reaction, in which pentamethylcyclopentadienyl rutheniumchloride complex is used as the catalyst to catalyze the azide-alkynecycloaddition.

For the sake of illustration, the functional elements linked to thelinking arms are referred to as the first elements. As could beappreciated, the number of the first elements carried by the presentlinker unit depends on the number of K residues of the center core (andthus, the number of the linking arms). Accordingly, one of ordinaryskill in the art may adjust the number of the first elements of thelinker unit as necessary, for example, to achieve the desired targetingor therapeutic effect.

An example of a linker unit 10C having the first elements is illustratedFIG. 1C. Other than the features discussed hereafter, FIG. 1C is quitesimilar to FIG. 1B. First, there are five K residues in the center core11 d, and accordingly, five linking arms 20 a-20 e are linked thereto,respectively. Second, the linker unit 10C has five first elements 30a-30 e linked to each of the linking arms 20 a-20 e. As discussed below,the optional tetrazine group 72 allows for the conjugation with anadditional functional element, another molecular construct (see, Part IIor Part III below).

In order to increase the intended or desired effect (e.g., thetherapeutic effect), the present linker unit may further comprise asecond element in addition to the first element. For example, the secondelement can be either a targeting element or an effector element. Inoptional embodiments of the present disclosure, the first element is aneffector element, while the second element may be another effectorelement, which works additively or synergistically with or independentlyof the first element. Still optionally, the first and second elementsexhibit different properties; for example, the first element is atargeting element, and the second element is an effector element, andvice versa. Alternatively, the first element is an effector element, andthe second element is an element capable of improving thepharmacokinetic property of the linker unit, such as solubility,clearance, half-life, and bioavailability. The choice of a particularfirst element and/or second element depends on the intended applicationin which the present linker unit (or multi-arm linker) is to be used.Examples of these functional elements are discussed below in PartI-(iii) of this specification.

Structurally, the second element is linked to the azide, alkyne,tetrazine, or strained alkyne group at the N- or C-terminus of thecenter core. Specifically, the second element may be optionallyconjugated with a short PEG chain (preferably having 2-12 repeats of EGunits) and then linked to the N- or C-terminal amino acid residue havingan azide group or an alkyne group (e.g., AHA residue or HPG residue).Alternatively, the second element may be optionally conjugated with theshort PEG chain and then linked to the coupling arm of the center core.

According to some embodiments of the present disclosure, the center corecomprises an amino acid having an azide group (e.g., the AHA residue) atits N- or C-terminus; and accordingly, a second element having an alkynegroup is linked to the N- or C-terminus of the center core via the CuAACreaction. According to other embodiments of the present disclosure, thecenter core comprises an amino acid having an alkyne group (e.g., theHPG residue) at its N- or C-terminus; and a second element having anazide group is thus capable of being linked to the N- or C-terminus ofthe center core via the CuAAC reaction.

FIG. 1D provides an example of the present linker unit 10D carrying aplurality of first elements and one second element. In this example, thecenter core 11 c comprises one HPG (G^(HP)) residue and five lysine (K)residues. Five linking arms 20 a-20 e are respectively linked to thefive K residues of the center core 11 c; and five first elements 30 a-30e are respectively linked to said five linking arms 20 a-20 e via thethiol-maleimide reaction. In addition to the first elements, the linkerunit 10D further comprises one second element 50 that is linked to oneend of a short PEG chain 62. Before being conjugated with the centercore 11 c, the other end of the short PEG chain 62 has an azide group.In this way, the azide group may react with the HPG residue that havingan alkyne group via CuAAC reaction, so that the second element 50 islinked to the center core 11 c. The solid dot 40 depicted in FIG. 1Drepresents the chemical bond resulted from the CuAAC reaction occurredbetween the HPG residue and the azide group.

Alternatively, the second element is linked to the center core via acoupling arm. According to certain embodiments of the presentdisclosure, the coupling arm has a tetrazine group, which can beefficiently linked to a second element having a TCO group via the iEDDAreaction. According to other embodiments of the present disclosure, thecoupling arm has a TCO group, which is capable of being linked to asecond element having a tetrazine group via the iEDDA reaction. In theiEDDA reaction, the strained cyclooctene that possess remarkablydecreased activation energy in contrast to terminal alkynes is employed,and thus eliminates the need of an exogenous catalyst.

Reference is now made to FIG. 1E, in which the center core 11 d of thelinker unit 10E comprises a terminal cysteine (C) residue and fivelysine (K) residues. As depicted in FIG. 1E, five linking arms 20 a-20 eare respectively linked to the five K residue of the center core 11 d,and then five first elements 30 a-30 e are respectively linked to thefive linking arms 20 a-20 e via thiol-maleimide reactions. The cysteineresidue is linked to the coupling arm 60, which, before being conjugatedwith the second element, comprises a tetrazine group or a TCO group atits free-terminus. In this example, a second element 50 linked with ashort PEG chain 62 having a corresponding TCO or tetrazine group can belinked to the coupling arm 60 via the iEDDA reaction. The ellipse 70 asdepicted in FIG. 1E represents the chemical bond resulted from the iEDDAreaction occurred between the coupling arm 60 and the short PEG chain62.

According to other embodiments of the present disclosure, before theconjugation with a second element, the coupling arm has an azide group.As such, the coupling arm can be linked to the second element having astrained alkyne group (e.g., the DBCO, DIFO, BCN, or DICO group) at thefree-terminus of a short PEG chain via SPAAC reaction (see, scheme 3),and vice versa.

Reference is now made to FIG. 1F, in which the linker unit 10F has astructure similar to the linker unit 10E of FIG. 1E, except that thecoupling arm 60 comprises an azide or a strained alkyne group (e.g., theDBCO, DIFO, BCN, or DICO group), instead of the tetrazine or TCO group.Accordingly, the second element 50 linked with a short PEG chain 62 mayhave a corresponding strained alkyne (e.g., DBCO, DIFO, BCN, or DICO) orazide group, so that it can be linked to the coupling arm 60 via theSPAAC reaction. The diamond 90 as depicted in FIG. 1F represents thechemical bond resulted from the SPAAC reaction occurred between thecoupling arm 60 and the short PEG chain 62.

Scheme 4 is an exemplary illustration of the process of preparing thepresent linker unit. In step 1, the center core comprising the aminoacid sequence of (GSK)₃ and a L-azidohomoalanine (AHA) residue at theC-terminus thereof is prepared. In step 2, three linking arms arerespectively linked to the lysine (K) residues of the center core viaforming an amide bond between the NHS group and the amine group; thelinking arm linked to the center core has a maleimide (Mal) group at thefree-terminus thereof. In step 3, three anti-A antigen scFvs (scFv α A)as the first element are respectively linked to the linking arms via thethiol-maleimide reaction. Meanwhile, in step 4, one anti-B antigen scFv(scFv α B) as the second element is linked with a short PEG chain thathas 4 repeats of EG units and a DBCO group at the free terminus.Finally, in step 5, the second element is linked to the AHA residue ofthe center core via the SPAAC reaction.

Scheme 5 illustrates another example of the process for preparing thepresent linker unit. In step 1, the center core comprising the aminoacid sequence of (K-Xaa)₃ and a cysteine residue at the C-terminusthereof is prepared. In step 2, a PEG chain (as the coupling arm) thathas the maleimide (Mal) group at one terminus and a tetrazine group atthe other terminus is linked to the cysteine residue via thethiol-maleimide reaction. Then, in step 3, three linking arm arerespectively linked to the lysine (K) residues of the center core. Next,three anti-A antigen scFvs (scFv α A) as the first elements arerespectively linked to the linking arms via the thiol-maleimide reactionas described in step 4. Meanwhile, in step 5, one anti-B antigen scFv(scFv α B) as the second element is linked with a short PEG chain thathas 3 repeats of EG units and a TCO group at the free terminus. Finally,in step 6, the second element is linked to the coupling arm via theiEDDA reaction.

PEGylation is a process, in which a PEG chain is attached or linked to amolecule (e.g., a drug or a protein). It is known that PEGylationimparts several significant pharmacological advantages over theunmodified form, such as improved solubility, increased stability,extended circulating life, and decreased proteolytic degradation.According to one embodiment of the present disclosure, the secondelement is a PEG chain, which has a molecular weight of about 20,000 to50,000 Daltons.

FIG. 1G provides an alternative example of the present linker unit(linker unit 10G), in which five first elements 30 are respectivelylinked to the lysine residues via the linking arms 20, and the HPG(G^(HP)) residue of the center core Ile is linked with a PEG chain 80via the CuAAC reaction. The solid dot 40 depicted in FIG. 1G representsthe chemical bond resulted from the CuAAC reaction occurred between theHPG residue and the PEG chain 80.

FIG. 1H provides another example of the present disclosure, in which theN-terminus of the center core 11 d is a cysteine residue that is linkedto a coupling arm 60. A PEG chain 80 can be efficiently linked to thecoupling arm 60 via the iEDDA reaction. The ellipse 70 of the linkerunit 10H represents the chemical bond resulted from the iEDDA reactionoccurred between the coupling arm 60 and the PEG chain 80.

FIG. 1I provides an alternative example of the present linker unit, inwhich the linker unit 10I has a structure similar to the linker unit 10Gof FIG. 1G, except that the PEG chain 80 is linked to the coupling arm60 via the SPAAC reaction. The diamond 90 depicted in FIG. 1I representsthe chemical bond resulted from the SPAAC reaction occurred between thecoupling arm 60 and the PEG chain 80.

According to some embodiments of the present disclosure, in addition tothe first and second elements, the present linker unit further comprisesa third element. In this case, one of the N- and C-terminus of thecenter core is an amino acid having an azide group or an alkyne group,while the other of the N- and C-terminus of the center core is acysteine residue. The lysine residues of the center core arerespectively linked with the linking arms, each of which has a maleimidegroup at its free terminus; whereas the cysteine residue of the centercore is linked with the coupling arm, which has a tetrazine group or astrained alkyne group at its free terminus. As described above, thefirst element is therefore linked to the linking arm via thethiol-maleimide reaction, and the second element is linked to thecoupling arm via the iEDDA reaction. Further, a third element is linkedto the terminal amino acid having an azide group or an alkyne group viathe CuAAC reaction or SPAAC reaction.

Reference is now made to the linker unit 10J of FIG. 1J, in which thecenter core 11 f has an HPG (G^(HP)) residue at the N-terminus thereofand a cysteine residue at the C-terminus thereof. The linking arms 20and the coupling arm 60 are respectively linked to the lysine (K)residues and the cysteine (C) residue of the center core 11 f. Further,five first elements 30 are respectively linked to the five linking arms20, the second element (i.e., the PEG chain) 80 is linked to thecoupling arm 60, and the third element 50 is linked to the HPG residuevia the short PEG chain 62. The solid dot 40 indicated the chemical bondresulted from the CuAAC reaction occurred between the HPG residue andthe short PEG chain 62; while the ellipse 70 represents the chemicalbond resulted from the iEDDA reaction occurred between the coupling arm60 and the PEG chain 80.

FIG. 1K provides another embodiment of the present disclosure, in whichthe linker unit 10K has the similar structure with the linker unit 10Jof FIG. 1J, except that the short PEG chain 62 is linked with the HPGresidue via the SPAAC reaction, instead of the iEDDA reaction. Thediamond 90 in FIG. 1K represents the chemical bond resulted from theSPAAC reaction occurred between the short PEG chain 62 and the HPGresidue.

In the preferred embodiments of this disclosure, the linking arms have amaleimide group in the free terminus for conjugating with first elementshaving the sulfhydryl group via the thiol-maleimide reaction. Also,there is one cysteine residue or an amino acid residue with an azide oralkyne group at a terminus of the peptide core for attaching a couplingarm for linking a second element.

It is conceivable for those skilled in the arts that variations may bemade. A conjugating group, other than maleimide, such as azide, alkyne,tetrazine, or strained alkyne may be used for the free terminus of thelinking arms, for linking with first elements with a CuAAC, iEDDA, orSPAAC reaction. Also the cysteine residue (or an amino acid residue withan azide or alkyne group) of the peptide core needs not to be at the N-or C-terminus. Furthermore, two or more of such residues may beincorporated in the peptide core to attach multiple coupling arms forlinking a plural of second elements.

In the case where the linker unit (or multi-arm linker) comprises onlythe first element but not the second and/or third element(s), the firstelement is an effector element that may elicit a therapeutic effect in asubject. On the other hand, when the present linker unit compriseselements in addition to first element(s), then at least one of theelements is an effector element, while the other may be another effectorelement, a targeting element, or an element capable of enhancing one ormore pharmacokinetic properties of the linker unit (e.g., solubility,clearance, half-life, and bioavailability). For example, the linker unitmay have two different kinds of effector element, one effector elementand one targeting element or one pharmacokinetic property-enhancingelement, two different kinds of targeting elements and one kind ofeffector element, two different kinds of effector elements and one kindof targeting element, or one kind of targeting element, one kind ofeffector element and one element capable of improving thepharmacokinetic property of the linker unit.

According to some embodiments of the present disclosure, the targetingelement is an antibody fragment specific for a human leukocyte antigen(HLA) allotype present only on cells of the donor transplant and not oncells of the recipient, such as the HLA-A, HLA-B, and HLA-C allotype.

Also, the effector element according to embodiments of the presentdisclosure is an immunosuppressant, an immune checkpoint protein, or anantibody fragment specific for CD25. Illustrative examples ofimmunosuppressant are inhibitors of mammalian target of rapamycin(mTOR), e.g. sirolimus and everolimus. Another set of immunosuppressantsare inhibitors of calcineurin, e.g. tacrolimus. Immune checkpointproteins are those involve in immune checkpoint, such as theextracellular domain of cytotoxic T lymphocyte associated protein 4(CTLA-4, also known as CD151) and the extracellular domain of programmeddeath-ligand 1 (PD-L1, also known as CD274).

The present disclosure also pertains to method for treatingtransplantation rejection in a subject receiving a donor transplant ortissue, or cells using the suitable multi-arm linker. Generally, themethod comprises the step of administering to a subject in need of suchtreatment an effective amount of the multi-arm linker according toembodiments of the present disclosure.

Compared with previously known therapeutic constructs, the presentmulti-arm linker (or linker unit) discussed in Part I is advantageous intwo points:

(1) The number of the functional elements may be adjusted in accordancewith the needs and/or applications. The present linker unit may comprisetwo elements (i.e., the first and second elements) or three elements(i.e., the first, second, and third elements) in accordance with therequirements of the application (e.g., the disease being treated, theroute of administration of the present linker unit, and the bindingavidity and/or affinity of the antibody carried by the present linkerunit). For example, when the present linker unit is directly deliveredinto the tissue/organ, one element acting as the effector element may beenough, thus would eliminate the need of a second element acting as thetargeting element. However, when the present linker unit is deliveredperipherally (e.g., oral, enteral, nasal, topical, transmucosal,intramuscular, intravenous, or intraperitoneal injection), it may benecessary for the present linker unit to simultaneously comprise atargeting element that specifically targets the present linker unit tothe lesion site; and an effector element that exhibits a therapeuticeffect on the lesion site. For the purpose of increasing the targetingor treatment efficacy or increasing the stability of the present linkerunit, a third element (e.g., a second targeting element, a secondeffector element, or a PEG chain) may be further included in the presentlinker unit.

(2) The first element is provided in the form of a bundle. As describedabove, the number of the first element may vary with the number oflysine residue comprised in the center core. If the number of lysineresidue in the center core ranges from 2 to 15, then at least two firstelements may be comprised in each linker unit. Thus, instead ofproviding one single molecule (e.g., immunosuppressant drug andantibody) as traditional therapeutic construct or method may render, thepresent linker unit is capable of providing more functional elements(either as targeting elements or as effector elements) at one time,thereby greatly improves the therapeutic effect.

In certain therapeutic applications, it is desirable to have a singlecopy of a targeting or effector element. For example, a single copy of atargeting element can be used to avoid unwanted effects due to overlytight binding. This consideration is relevant, when the scFv has arelatively high affinity for the targeted antigen and when the targetedantigen is a cell surface antigen on normal cells, which are nottargeted diseased cells. In still another example, it is desirable tohave only one copy of long-chain PEG for enhancing pharmacokineticproperties. Two or more long PEG chains may cause tangling and affectthe binding properties of the targeting or effector elements.

PART II Fc-based Molecular Constructs for Treating TransplantationRejection and Uses Thereof

In the broad sense of the Fc-based configuration, immunoglobulinantibody can serve as the base of a targeting or effector element, andits corresponding effector or targeting element can be incorporated atthe C-terminal of its two heavy γ chains in the form of scFv domains.For a typical “Fc-based” configuration, two-chain IgG.Fc is used as thebase of the molecular platform. Each of the polypeptide chain is fusedwith one or two targeting and one or two effector elements, for a totalof two to three elements on each chain. The T-E molecule with anFc-based configuration will have a total of four to six elements (e.g.,scFv, proteins, or drug bundles). Optionally, the Fc portion of themolecular constructs also carries Fc-mediated effector functions, ADCC,and/or complement-mediated activation. While in certain otherapplications, such Fc-mediated effector functions are avoided.

By selecting the T-E elements of the present Fc-based molecularconstruct, the molecular construct can be used to prevent and/or treatconditions associated with transplantation rejection. The presentdisclosure is also advantageous in that, in some embodiments, itutilizes the linker unit proposed in the present disclosure, whichprovides a facile means for controlling the number of the targeting andeffector elements of the present Fc-based molecular constructs.Depending on the targeting and/or effector elements selected, thepresent Fc-based molecular construct may take different configurations,which are discussed below, respectively.

In many molecular constructs of this invention, the preferred targetingor effector elements are Fab, Fv, single-chain Fv (scFv), single-domainantibody (sdAb), or other antigen-binding fragments of antibodies. Forthe scFv, a polypeptide linker with a sequence of (GGGGS)₂₋₅ is placedbetween V_(L) and V_(H), or between V_(H) and V_(L), according tocertain preferred embodiments Other sequences of flexible nature andwithout a rigid secondary structure, such as the linking sequencesbetween CH1 and CH2 domains and CH2 and CH3 domains of some humanimmunoglobulin isotypes, may also be used. In some optional embodiments,a polypeptide linker of (GGGGS)₁₋₃ and a terminal cysteine residue isconfigured at the C-terminal of the scFv or other antibody fragment ortherapeutic peptide. The sulfhydryl group is for conjugating with amaleimide group at the end of the linking arms extending from a linkerunit.

In a first series of Fc-based molecular constructs, the targetingelement can be an antibody (or a fragment thereof) specific for an HLAallotype, and the elector element can be an antibody (or an antibodyfragment) specific for CD25. Some illustrative structures of thisFc-based molecular construct are discussed below.

Referring to FIG. 2A, which is a schematic diagram illustrating anFc-based molecular construct 800A according to certain embodiments ofthe present disclosure. As illustrated, the Fc-based molecular construct800A comprises two identical CH2-CH3 chains 810, a first pair ofeffector elements E1 (e.g., scFvs specific for CD25) linked to theN-termini of the CH2-CH3 chains 810, and a first pair of targetingelements T1 (e.g., scFvs specific for an HLA allotype) linked to theC-termini of the CH2-CH3 chains 810.

The Fc-based molecular construct 800B illustrated in FIG. 2B is quitesimilar to the Fc-based molecular construct 800A of FIG. 2A instructure, except that the two effector elements E1 are respectivelylinked to the C-termini of the CH2-CH3 chains 810, while the twotargeting elements T1 are respectively linked to the N-termini of theCH2-CH3 chains 810.

According to certain embodiments, both the effector elements andtargeting elements are linked to the N-termini of the CH2-CH3 chains.For example, when both the effector element and the targeting elementare in the form of single-chain variable fragments (scFvs), the effectorelement and the targeting element may be linked in a tandem or diabodyconfiguration, thereby forming a bispecific scFv that is linked to theN-terminus of the CH2-CH3 chain. The Fc-based molecular construct 800C(FIG. 2C) comprises an Fc portion, and each CH2-CH3 chain 810 has aT1-E1 bispecific scFv linked to the N-terminus thereof.

In some examples, the first pair of effector elements or the first pairof the targeting elements takes a Fab configuration (i.e., consisting ofthe V_(H)-CH1 domain and the V_(L)-Cκ domain); this Fab fragment islinked to the N-termini of the CH2-CH3 chains, so that the Fc-basedmolecular construct adopts an IgG configuration. In these cases, thepair of elements that is not in the Fab configuration may be linked tothe C-termini of the pair of CH2-CH3 segments. For example, in theFc-based molecular construct 800D of FIG. 3, each of the two targetingelements T1 comprises the V_(H)-CH1 domain 820 and the V_(L)-Cκ domain825, thereby forming a Fab configuration 830 that is linked to theN-termini of the CH2-CH3 chains 810, so that the Fc-based molecularconstruct 800D adopts the IgG configuration. In this case, the pair ofeffector elements E1 is linked to the C-termini of the pair of CH2-CH3chains 810.

As described above, the present Fc-based molecular construct may carry atotal of six elements at most. The additional elements may be a secondpair of effector elements or a second pair of targeting elements.

In a second series of Fc-based molecular constructs, the targetingelement is an antibody or a fragment thereof (e.g., an scFv specific foran HLA allotype), whereas the effector element is a protein or peptide(e.g., an immune checkpoint protein or a fragment thereof).

Referring to FIG. 4A, which is a schematic diagram illustrating anFc-based molecular construct 1200A comprises a pair of targetingelements T1 (as scFvs) linked to the N-termini of the pair of CH2-CH3segments 1210, and a pair of effector elements E1 (in the form oftherapeutic peptides) linked to the C-termini of the pair of CH2-CH3segments 1210. Alternatively, in the Fc-based molecular construct 1200Bof FIG. 4B, the pair of targeting elements T1 (as scFvs) is linked tothe C-termini of the pair of CH2-CH3 segments 1210, whereas the pair ofeffector elements E1 (in the form of therapeutic peptides) is linked tothe N-termini of the pair of CH2-CH3 segments 1210.

In some embodiments, the pair of the targeting elements takes a Fabconfiguration (i.e., consisting of the V_(H)-CH1 domain and the V_(L)-Cκdomain); this Fab fragment is linked to the N-termini of the CH2-CH3chains, so that the Fc-based molecular construct adopts an IgGconfiguration. In these cases, the pair of effector elements may belinked to the C-termini of the pair of CH2-CH3 segments.

For example, in the Fc-based molecular construct 1200C of FIG. 4C, eachof the two targeting elements T1 comprises the V_(H)-CH1 domain 820 andthe V_(L)-Cκ domain 825, thereby forming a Fab configuration 830 that islinked to the N-termini of the CH2-CH3 chains 810, so that the Fc-basedmolecular construct 1200C adopts the IgG configuration. In this case,the pair of effector elements E1 (a therapeutic peptide) is linked tothe C-termini of the pair of CH2-CH3 chains 810.

In a third series of Fc-based molecular constructs, the targetingelement can be an antibody or a fragment thereof, and the electorelement can be a drug bundle comprising a plurality of immunosuppressantmolecules.

In these cases, the Fc-based molecular constructs for treating diseasedcells may have the configuration of molecular construct 1000A of FIG. 5Aor molecular construct 1000B of FIG. 5B. As illustrated in FIG. 5A, theeffector elements E1 (for example, drug bundles) are linked to theC-termini of the pair of CH2-CH3 segments 1010, whereas the targetingelements T1 (in this case, an scFv) are linked to the N-termini of thepair of CH2-CH3 segments 1010. According to alternative embodiments, themolecular construct 1000B (see, FIG. 5B) has a pair of targetingelements T1 that takes the form of a Fab 1030. Specifically, the Fab1030 configuration comprises the V_(H)-CH1 domain 1020 and the V_(L)-Cκdomain 1025, and is linked to the N-termini of the pair of CH2-CH3segments 1010, so that the Fc-based molecular construct 1000A adopts theIgG configuration. In this case, the pair of effector elements E1 islinked to the C-termini of the pair of CH2-CH3 chains 1010.

As could be appreciated, the drug bundle (i.e., effector element E1) maybe provided as the linker unit discussed in the present disclosure (see,for example FIG. 1A to FIG. 1C). According to the principles and spiritsof the present disclosure, a targeting construct (comprising the pair ofCH2-CH3 segments 1010 and the targeting elements T1) and the drugbundles (for use as effector elements E1) can be prepared separately andthen conjugated with each other.

In either series according to embodiments of the present disclosure, theCH2-CH3 chains are adopted from human immunoglobulins γ1 or γ4. Ingeneral, γ1 is chosen, when Fc-mediated functions, such asantibody-dependent cellular cytotoxicity (ADCC) and complement-mediatedactivity (inflammatory activation or target cell lysis), are desired. Inthe case where Fc-mediated functions are avoided, γ4 is chosen forconstructing the present Fc-based molecular constructs.

According to embodiments of the present disclosure, the drug bundlecomprises a center core, a plurality of linking arms, and optionally, acoupling arm. The center core may be a polypeptide comprising aplurality of lysine (K) residues, according to various embodiments ofthe present disclosure. Each of the linking arms has one terminus thatis linked to the center core by reacting with the amine side chain ofthe K residues of the polypeptide core. The linking arm also carries amaleimide group at the free terminus thereof, wherein each of the drugmolecules is linked to the center core via connecting through thelinking arm by reacting with the maleimide group. According to optionalembodiments of the present disclosure, each of the effector elements E1is a drug bundle with 3-5 immunosuppressant molecules.

In the case where the center core is the polypeptide core, then theamino acid residue at the N- or C-terminus of the center core is acysteine residue or has an azide group or an alkyne group. According tocertain embodiments, for polypeptide cores with a terminal amino acidresidue having the azide group, the drug bundle is linked to the peptideextension via the SPAAC reaction or CuAAC reaction occurred between saidterminal residue and the C-terminus of the peptide extension.Alternatively, when the polypeptide cores has a terminal amino acidresidue with the alkyne group, the drug bundle is linked to the peptideextension via the CuAAC reaction occurred between said terminal residueand the C-terminus of the peptide extension. Still alternatively, forpolypeptide cores with a terminal residue that is cysteine, the drugbundle further comprises said coupling arm. Specifically, the couplingarm has one terminus linked to the center core by reacting with thecysteine residue of the polypeptide core. The coupling arm also carriesan alkyne group, azide group, tetrazine group, or strained alkyne groupat the free terminus thereof, so that the drug bundle is linked to theC-terminus of the peptide extension via the iEDDA reaction (for couplingarms with the tetrazine or cyclooctene group), SPAAC (for coupling armswith the azide or cyclooctyne group) reaction or CuAAC reaction (forcoupling arms with the alkyne or azide group) occurred therebetween.

According to certain embodiments, the present Fc-based molecularconstruct for treating diseased cells further comprises a pair ofpeptide extensions 1050 (see, FIGS. 10A and 10B) respectively having thesequence of (G₂₋₄S)₂₋₈C. As illustrated, the pair of peptide extensions1050 is linked to the C-termini of the pair of CH2-CH3 segments 1010.The cysteine residue at the C-terminus of the peptide extension islinked with a coupling arm 1055 via thiol-maleimide reaction occurredtherebetween. Also, before being conjugated with the effector element E1(in this case, a drug bundle), the free terminus of the conjugating arm(that is, the terminus that is not linked to the cysteine residue) ismodified with an alkyne, azide, strained alkyne, or tetrazine group, sothat the drug bundle is linked thereto via iEDDA reaction (see, FIG.5A), SPAAC (see, FIG. 5B), or CUAAC (not shown) reaction occurredtherebetween.

For example, in FIG. 5A, the coupling arm 1040 of the effector elementE1 (in this case, a drug bundle) is linked to the CH2-CH3 segment 1010via iEDDA reaction. The ellipse 1045 as depicted in FIG. 5A representsthe chemical bond resulted from the iEDDA reaction occurred between thepeptide extension 1050 and the effector element E1. As could beappreciated, an iEDDA reaction is occurred between a tetrazine group anda cyclooctene group, such as a transcyclooctene (TCO) group.

Alternatively, in FIG. 5B, the effector element E1 is linked to theCH2-CH3 segment 1010 via SPAAC reaction. The diamond 1045 as depicted inFIG. 5B represents the chemical bond resulted from the SPAAC reactionoccurred between the peptide extension 1050 and the effector element E1.Specifically, an SPAAC reaction is occurred between an azide group and astrained alkyne group (e.g., a cyclooctyne group, including,dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO),bicyclononyne (BCN), and dibenzocyclooctyne (DICO) group).

In a third series of Fc-based molecular constructs, one of the targetingand effector elements can be a peptide.

As could be appreciated, the discussions above regarding the Fc regionand drug bundle of the Fc-based molecular constructs are also applicablehere, and hence, detailed description regarding the same is omittedherein for the sake of brevity.

According to the embodiments of the present disclosure, there is ampleflexibility in the numbers of targeting elements and effector elementsthat can be installed, allowing higher targeting specificity andeffector activity. The linker units for a targeting element and for aneffector element can be prepared separately before joining. In preparingADCs, the bundles of immunosuppressant can be prepared separatelywithout exposing the antibodies to harsh chemical conditions. In usingthis approach, the drug to antibody ratios (DAR) can be bettercontrolled than if the drugs are conjugated directly onto antibodymolecules. The adoption of the Fc-based molecular construct and drugbindle can accommodate the preparation of various targeting/effectorpharmaceutical molecules. Another advantage is that IgG.Fc is notcontained in the molecular constructs and can minimize potentialFc-mediated effects, such as complement-mediated activation, when sucheffects are not desired.

Now that the basic structural arrangements of the Fc-based molecularconstructs have been discussed above, certain combinations of particulareffector element(s) and targeting element(s) are provided below for theillustration purpose.

In constructing Fc-based molecular constructs for preventing and/ortreating diseases/conditions associated with transplantation rejectionin a subject (recipient) receiving a donor transplant (e.g., an organ, atissue, or cells), one may use an antibody (or a fragment thereof)specific for an HLA allotype that is present only on cells of the donortransplant and not on cells of the recipient as the targeting element.

Regarding the effector element for treating transplantation rejection,it can be an immune checkpoint protein, an antibody fragment specificfor CD25, or a drug bundle comprising as plurality of immunosuppressantmolecules. Immune checkpoint proteins are those involve in immunecheckpoint, such as the extracellular domain of cytotoxic T lymphocyteassociated protein 4 (CTLA-4, also known as CD151) and the extracellulardomain of programmed death-ligand 1 (PD-L1, also known as CD274).Illustrative examples of immunosuppressant are inhibitors of mammaliantarget of rapamycin (mTOR), e.g. sirolimus and everolimus. Another setof immunosuppressants are inhibitors of calcineurin, e.g. tacrolimus.Fingolimod and derivatives thereof (e.g., fingolimod phosphate) are alsoexamples of suitable immunosuppressants.

The essence of this invention is the rationalization and conception ofthe specific combination or pairing of the targeting and effectorelements. The adoption of Fc-fusion configuration in the molecularconstructs is a preferred embodiment. It is conceivable for thoseskilled in the arts to link the pairs of targeting and effector elementsof this invention employing other molecular platforms, such as peptides,proteins (e.g., albumin), polysaccharides, polyethylene glycol, andother types of polymers, which serve as a structural base for attachingmultiple molecular elements.

The present disclosure also pertains to method for preventing and/ortreating diseases/conditions associated with transplantation rejectionin a subject (recipient) receiving a donor transplant (e.g., an organ, atissue, or cells). Generally, the method comprises the step ofadministering to a subject in need of such treatment an effective amountof the Fc-based molecular construct according to embodiments of thepresent disclosure.

EXPERIMENTAL EXAMPLES Example 1 Synthesis of Peptide 1 (SEQ ID NO: 18),Peptide 2 (SEQ ID NO: 26), and Peptide 3 (SEQ ID NO: 19) as PeptideCores, and Conjugation of SH Group of Cysteine Residue withMaleimide-PEG₃-Transcyclooctene (TCO) as a Coupling Arm

Each of peptides 1 to 3 (Chinapeptide Inc., Shanghai, China) wasdissolved in 100 mM sodium phosphate buffer (pH 7.0) containing 50 mMNaCl and 5 mM EDTA at a final concentration of 2 mM. The dissolvedpeptide was reduced by 1 mM tris(2-carboxyethyl)phosphine (TCEP) at 25°C. for 2 hours. For conjugating the SH group of cysteine residue withmaleimide-PEG₃-TCO (Conju-probe Inc.) to create a functional linkinggroup TCO, the peptide and maleimide-PEG₃-TCO were mixed at a 1/5 ratioand incubated at pH 7.0 and 4° C. for 18 hours. TCO-conjugated peptideswere purified by reverse phase HPLC on a Supelco C18 column (250 mm×10mm; 5 μm), using a mobile phase of acetonitrile and 0.1% trifluoroaceticacid, a linear gradient of 0% to 100% acetonitrile over 30 minutes, at aflow rate of 1.0 mL/min and a column temperature of 25° C.

The present TCO-peptide 1, as illustrated below, had a molecular weightof 2,078.9 Daltons.

         Ac          | TCO-PEG₃-CGGSGGSGGSKGSGSKGSK

The present TCO-peptide 2, as illustrated below, had a molecular weightof 2,020.09 Daltons.

         Ac          | TCO-PEG₃-CGSKGSKGSKGSKGSK

The present TCO-peptide 3, as illustrated below, had a molecular weightof 3,381.85 Daltons.

         Ac          | TCO-PEG₃-CGSKGSKGSKGSKGSKGSKGSKGSKGSKGSK

Example 2 Synthesis of Linker Unit by Conjugating NHS-PEG₁₂-Mal to NH₂Groups of TCO-peptides 1

Three linking arms of PEG₁₂-maleimide were attached to the peptide coreTCO-peptide 1. The crosslinker, NHS-PEG₁₂-maleimide(succinimidyl-[(N-maleimido-propionamido)-dodecaethyleneglycol] ester,was purchased from Conju-probe Inc. The conjugation procedure wasperformed per the manufacturer's instruction; the peptide with lysineresidues was dissolved in the conjugation buffer, phosphate bufferedsaline (PBS, pH 7.5) at 100 mM. NHS-PEG₁₂-maleimide crosslinker wasadded to the dissolved peptide at a final concentration of 1 mM (10-foldmolar excess over 0.1 mM peptide solution). The reaction mixtures wereincubated for 18 hours at room temperature. Themaleimide-PEG₁₂-conjugated TCO-peptide 1 was purified by reverse phaseHPLC on a Supelco C18 column (250 mm×4.6 mm; 5 μm), using a mobile phaseof acetonitrile and 0.1% trifluoroacetic acid, a linear gradient of 0%to 100% acetonitrile over 30 minutes, at a flow rate of 1.0 ml/min and acolumn temperature of 25° C.

As illustrated below, the thus-synthesized maleimide-PEG₁₂-conjugatedTCO-peptide 1 carried one coupling arm with a TCO group and three PEGlinking arms with maleimide groups; it had a molecular weight of 4,332Daltons.

Example 3 Synthesis of Sirolimus-Gly and Sirolimus-diGly Molecule

Sirolimus monoglycine (sirolimus-Gly) and sirolimus di-glycine(sirolimus-diGly) were designed and prepared under a contractualarrangement with Dr. Jiann-Jyh Huang's laboratory at the Department ofApplied Chemistry, National Chiayi University, Chiayi, Taiwan.

For the synthesis of sirolimus-Gly (7a) and sirolimus-diGly (7b),sirolimus (1) served as the starting material and was reacted withtrimethylsilyl chloride (TMSCl) using imidazole as the base to give28,40-bis-O-TMS sirolimus (see the following Scheme 6). Thetrimethylsilyl group at the 40-O position of 28,40-bis-O-TMS sirolimuswas selectively removed by imidazole and imidazole hydrochloride to give28-O-TMS sirolimus (2) in 82% total yield. Esterification of the 40-OHby tritylglycine (3) and tritylglycylglycine (4) using DCC as thecoupling agent and DMAP as the catalyst in CH₂Cl₂ gave 28-O-TMSsirolimus-GlyTrt (5a) and 28-O-TMS sirolimus-diGlyTrt (5b) in 75%and >99% yields, respectively. The trimethylsilyl group in 5a and 5b wasremoved under acidic conditions to afford sirolimus-GlyTrt (6a) in 99%yield and sirolimus-diGlyTrt (6b) in 85% yield. Deprotection of thetrityl group in 6a and 6b by HOBt in trifluoroethanol gave the desiredsirolimus-Gly (7a) and sirolimus-diGly (7b) in 61% and 27% yields,respectively.

Reagents and starting materials were used as purchased without furtherpurification. Analytical thin-layer chromatography (TLC) was performedon precoated plates (silica gel 60 F-254), purchased from Merck Inc.Purification by column chromatography was conducted using Merck ReagentsSilica Gel 60 (particle size of 0.063-0.200 mm, 70-230 mesh ASTM).Proton NMR spectra were recorded on an Agilent

400-MR (400 MHz) spectrometer with CD₃OD or DMSO-d₆ as solvent.Multiplicities are abbreviated as follows: s, singlet; d, doublet; t,triplet; q, quartet; m, multiplet. ESI-MS mass spectra were obtained ona Finnigan LCQ mass spectrometer. High-resolution mass spectra wereobtained by means of an LTQ Orbitrap XL mass spectrometer (Thermo FisherScientific). Tritylglycine (3) and tritylglycylglycine (4) were preparedaccording to reported procedures (Nogusa et al., 1995).

28-O-TMS Sirolimus (2). Sirolimus (1, 1.992 g, 2.179 mmol, 1.0 equiv)and imidazole (0.1494 g, 2.194 mmol. 1.0 equiv) in CH₂Cl₂ (109 mL) wereslowly added with trimethylsilyl chloride (TMSCl, 1.0 M in CH₂Cl₂, 13.0mL, 13.0 mmol, 6.0 equiv) in an ice bath. The reaction mixture wasstirred at 0° C. and the reaction was monitored by TLC. After thereaction was complete (about 10 minutes), the solution was concentratedunder reduced pressure. The residue was purified by flash columnchromatography using 50% EtOAc in hexanes as the eluent to give28,40-bis-O-TMS sirolimus (2.261 g, 2.136 mmol): ESI-MS: 1080.62(M+Na)⁺. The obtained 28,40-Bis-O-TMS sirolimus was mixed with imidazole(2.250 g, 33.05 mmol, 15 equiv) and imidazole hydrochloride (3.463 g,33.13 mmol, 16 equiv) in CH₂Cl₂ (218 mL). The reaction mixture wasstirred at room temperature and the reaction was monitored by TLC. Afterthe reaction was complete (about 3 hours), the solution was concentratedunder reduced and the residue was purified by flash columnchromatography using 50% EtOAc in hexanes as the eluent to give 28-O-TMSsirolimus (2, 1.772 g, 1.796 mmol) in 82% total yield: ESI-MS: 1008.58(M+Na)⁺.

28-O-TMS Sirolimus-GlyTrt (5a). A solution of 2 (0.305 g, 0.309 mmole,1.0 equiv), tritylglycine (3, 0.592 g, 1.87 mmol, 6.1 equiv), and DMAP(0.065 g, 0.532 mmol, 1.7 equiv) in anhydrous CH₂Cl₂ (10 mL) was slowlyadded with DCC (0.386 g, 1.87 mmol, 6.1 equiv) in anhydrous CH₂Cl₂ (5.0mL). The reaction mixture was stirred at room temperature and thereaction was monitored by TLC. After the reaction was complete (about 3hours), the solution was added with H₂O (1.0 mL) and the white DBUprecipitate was filtered. The filtrate was diluted with EtOAc and washedwith saturated NaHCO₃. The organic layer was dried over MgSO₄, filtered,and concentrated under reduced pressure. The residue was purified bycolumn chromatography using 25% EtOAc in hexanes as the eluent to give5a (300 mg, 0.233 mmol) in 75% yield.

28-O-TMS Sirolimus-diGlyTrt (5b). Compound 5b was prepared as the sameprocedure to 5a using 2 (0.305 g, 0.309 mmol, 1.0 equiv),tritylglycylglycine (4, 0.347 g, 0.927 mmol, 3.0 equiv), DMAP (11 mg,0.090 mmol, 0.30 equiv), and DCC (0.240 g, 1.16 mmol, 3.8 equiv). Thereaction gave 5b (0.535 g, 0.398 mmol) in >99% yield: HRMS calcd forC₇₇H₁₀₇N₃NaO₁₅Si (M+H)⁺ 1364.7364, found 1364.7275.

Sirolimus-GlyTrt (6a). Compound 5a (0.193 g, 0.150 mmol, 1.0 equiv) inTHF (10 mL) was added with H₂O (2.0 mL) and 0.10 N HCl (0.50 mL) in anice bath. The reaction mixture was stirred at room temperature for 12hours. The solution was added with NaHCO₃ (0.10 M, 1.0 mL) and dilutedwith EtOAc. The solution was washed with water, dried over MgSO₄, andconcentrated under reduced pressure. The residue was purified by columnchromatography using 50% EtOAc in hexanes as the eluent to give 6a (180mg, 0.148 mmol) in 99% yield. HRMS calcd for C₇₂H₉₇N₂O₁₄ (M+H)⁺1213.6934, found 1213.6887.

Sirolimus-diGlyTrt (6b). Compound 6b was prepared as the same procedureto 6a using 5b (0.535 g, 0.398 mmol, 1.0 equiv). The reaction gave 6b(0.431 g, 0.339 mmol) in 85% yield: HRMS calcd for C₇₄H₁₀₀N₃O₁₅ (M+H)⁺1270.7149, found 1270.7054.

Sirolimus-Gly (7a). Compound 6a (0.168 g, 0.138 mmol, 1.0 equiv) wasdissolved in 0.10 M HOBt solution in trifluorothanol (1.0 mL) and thereaction was monitored by TLC. After the reaction was complete (˜12 h),the solution was added with H₂O (0.10 mL) and diluted with EtOAc. Thesolution was washed with saturated Na₂CO₃, dried over MgSO₄, filtered,and concentrated under reduced pressure. The residue was purified bycolumn chromatography to give 7a (82 mg, 0.084 mmol) in 61% yield: HRMScalcd for C₅₃H₈₃N₂O₁₄ (M+H)⁺ 971.5839, found 971.5806; ¹H NMR (CD₃OD) δ6.48-6.36 (m, 2 H), 6.30-6.03 (m, 3 H), 5.47 (s, 1 H), 5.42 (d, 1 H),5.21 (d, 1 H), 5.06 (d, 1 H), 4.68 (s, 1 H), 4.15 (d, 1 H), 4.08 (d, 1H), 3.98 (d, 1 H), 3.66 (d, 1 H), 3.56-3.50 (m, 1 H), 3.41 (s, 2 H),3.36 (s, 3 H), 3.26 (s, 3 H), 3.12 (s, 3 H), 2.84-2.80 (m, 1 H),2.79-2.76 (m, 1 H), 2.48-2.40 (m, 2 H), 2.35-0.90 (m, 52 H).

Sirolimus-diGly (7b). Compound 7b was prepared as the same procedure to7a using 6b (0.431 g, 0.339 mmol, 1.0 equiv). The reaction gave 7b (96mg, 0.093 mmol) in 27% yield: ¹H NMR (DMSO-d₆) δ 6.70-6.53 (m, 1 H),6.48-6.22 (m, 2 H), 6.23-6.00 (m, 3 H), 5.58-5.33 (m, 1 H), 5.29-5.10(m, 2 H), 4.98-4.84 (m, 2 H), 4.60-4.41 (m, 2 H), 4.14-4.01 (m, 5 H),3.99-3.46 (m, 2 H), 3.76-3.46 (m, 3 H), 3.21 (s, 3 H), 3.12 (s, 3 H),3.00 (s, 1 H), 2.94 (s, 3 H), 2.75-2.60 (m, 2 H), 2.39-2.28 (m, 1 H),2.26-2.16 (m, 1 H), 2.15-1.75 (m, 3 H), 1.68-0.53 (m, 45 H).

FIG. 6A shows mass spectrometric analysis of the thus-synthesizedsirolimus-Gly (compound 7a of scheme 6); MS (ESI) calculated forC₅₃H₈₂N₂O₁₄ 971.22. found 993.5668, corresponding to [M+Na]⁺. The threeisotopic peaks were also visible in the MS spectrum at 994.57, 995.574,and 996.58, corresponding to [M+Na+1]⁺, [M+Na+2]⁺, and [M+Na+3]⁺.

FIG. 6B shows mass spectrometric analysis of the thus-synthesizedsirolimus-diGly (compound 7b of scheme 6); MS (ESI) calculated forC₅₅H₈₅N₃O₁₅ 1028.27. found 1028.6067, corresponding to [M+H]⁺. The threeisotopic peaks were also visible in the MS spectrum at 1029.6113,1030.6152, and 1031.6191, corresponding to [M+H+1]⁺, [M+H+2]⁺, and[M+H+3]⁺.

Example 4 Conjugation of Sirolimus-Gly and Sirolimus-diGly Moleculeswith NHS-S-S-PEG₃-azido Linking Arm

In this example, the NH₂ group of the sirolimus-Gly and sirolimus-diGlymolecule was reacted with a hetero-bifunctional cleavable linker,NHS—S—S-PEG₃-azido (Conju-probe Inc.).

Briefly, sirolimus-Gly was dissolved in 100% DMSO at a finalconcentration of 50 mM, while NHS-S-S-PEG₃-azido was dissolved in 100%DMSO at a final concentration of 250 mM. 59.76 μl of theNHS-S-S-PEG₃-azido linker solution was added to 149.4 μl of thedissolved sirolimus-Gly solution at a final concentration of 5 mM(2-fold molar excess over 2.5 mM sirolimus-Gly solution). Then, 298.8 μlof a buffer solution containing 100 mM sodium phosphate buffer at pH 7.5and 2,480 μl of 100% DMSO were added to the reaction mixture to reach atotal volume of 2,988 μl. The reaction mixture was incubated for 3 hoursat room temperature, and then the solvent was evaporated under vacuum.

The product, Azido-PEG₃-S-S-conjugated sirolimus-Gly, was dissolved in65% acetonitrile; then purified by reverse phase HPLC on a Supelco C18column (250 mm×10.0 mm; 5 μm), using a mobile phase of acetonitrile and0.1% trifluoroacetic acid, a linear gradient of 50% to 100% acetonitrileover 20 minutes, at a flow rate of 3.0 mL/min and a column temperatureof 45° C.

FIG. 7A shows the mass spectrometric analysis of the thus-synthesizedazido-PEG₃-S-S-conjugated sirolimus-Gly, as illustrated below. MS (ESI)calculated for C₆₄H₁₀₁N₅O₁₈S₂ 1292.64; found 1314.6463, corresponding to[M+Na]⁺. The three isotopic peaks were also visible in the MS spectrumat 1315.65, 1316.6532, and 1317.6559, corresponding to [M+Na+1]⁺,[M+Na+2]⁺, and [M+Na+3]⁺.

Similarly, sirolimus-diGly was dissolved in 100% DMSO at a finalconcentration of 50 mM, and NHS-S-S-PEG₃-azido linker was dissolved in100% DMSO at a final concentration of 250 mM. 46.68 μl of theNHS-S-S-PEG₃-azido linker solution was then added to 116.7 μl of thedissolved sirolimus-diGly solution at a final concentration of 5 mM(2-fold molar excess over 2.5 mM sirolimus-diGly solution). Then, 233.4μl of a buffer solution containing 100 mM sodium phosphate buffer at pH7.5 and 1,937.22 μl of 100% DMSO were added to the reaction mixture toreach a total volume of 2,334 μl. The reaction mixture was incubated for3 hours at room temperature, and then the solvent was evaporated undervacuum. The product was purified using reverse phase HPLC following theprotocol described above.

FIG. 7B shows the mass spectrometric analysis of the thus-synthesizedazido-PEG₃-S-S-conjugated sirolimus-diGly, as illustrated below. MS(ESI) calculated for C₆₆H₁₀₄N₅O₁₉S₂ 1349.69; found 1371.6785,corresponding to [M+Na]⁺. The three isotopic peaks were also visible inthe MS spectrum at 1372.6817, 1373.682, and 1374.6828, corresponding to[M+Na+1]⁺, [M+Na+2]⁺, and [M+Na+3]⁺.

Example 5 Conjugation of Fingolimod and Fingolimod Phosphate Moleculewith NHS-PEG₅-NHS Cross-linker

Fingolimod was purchased from Biotang Inc. (Lexington, USA) andfingolimod phosphate from KM3 Scientific Corporation (New Taipei City,Taiwan). The NH₂ group of fingolimod molecule was reacted with ahomo-bifunctional crosslinker, NHS-PEG₅-NHS as shown in scheme 7.

Briefly, fingolimod was dissolved in 100% DMSO at a final concentrationof 10 mM, while NHS-PEG₅-NHS, a homo-bifunctional crosslinker, wasdissolved in 100% DMSO at a final concentration of 250 mM. To activatethe NH₂ group of fingolimod, 6% (v/v) of basic sodium phosphate buffer(pH12.7) was added to the fingolimod solution and then incubated for 10minutes. NHS-PEG₅-NHS crosslinker was added to the dissolved fingolimodsolution at a final concentration of 30 mM (3-fold molar excess over 10mM fingolimod solution). The reaction mixture was incubated for 3 hoursat room temperature.

Fingolimod phosphate was dissolved in 100% DMSO at a final concentrationof 5 mM, and NHS-PEG₅-NHS crosslinker was dissolved in 100% DMSO at afinal concentration of 250 mM. NHS-PEG₅-NHS crosslinker was added to thedissolved fingolimod phosphate solution at a final concentration of 15mM (3-fold molar excess over 5 mM fingolimod phosphate solution). Thereaction mixture was incubated for 3 hours at room temperature, thenadded 18% (v/v) acid sodium phosphate buffer (decreasing pH value of thebuffer solution) to quench the reaction. The solvent was evaporatedunder vacuum.

The NHS-PEG₅-conjugated fingolimod and NHS-PEG₅-conjugated fingolimodphosphate were respectively dissolved in 30% acetonitrile, then purifiedby reverse phase HPLC on a Supelco C18 column (250 mm×4.6 mm; 5 μm),using a mobile phase of acetonitrile and 0.1% trifluoroacetic acid, alinear gradient of 30% to 100% acetonitrile over 30 minutes, at a flowrate of 1.0 mL/min and a column temperature of 25° C.

FIG. 8 shows that the thus-synthesized NHS-PEG₅-conjugated fingolimod,as illustrated above in scheme 7, had a molecular weight of 725.41Daltons.

The present NHS-PEG₅-conjugated fingolimod phosphate, as illustratedbelow, had a molecular weight of 803.3 Daltons.

Example 6 Conjugation of Fingolimod Molecule with NHS-S-S-PEG₃-azidoLinking Arm

The NH₂ group of fingolimod molecule was reacted with ahetero-bifunctional cleavable linker, NHS-S-S-PEG₃-azido (Conju-probeInc.), at a 1:3 molar ratio. The product, azido-PEG₃-S-S-fingolimod waspurified by HPLC to remove the excess, unreacted fingolimod molecules.The procedures for conjugation and purification were similar to thosedescribed in the preceding example.

FIG. 9 shows the mass spectrometric analysis of the thus-synthesizedazido-PEG₃-S-S-conjugated fingolimod, as illustrated below. MS (ESI)calculated for C₃₀H₅₃N₄O₆S₂ 629.9007; found 651.321, corresponding to[M+Na]⁺. The three isotopic peaks were also visible in the MS spectrumat 652.315 and 653.328, corresponding to [M+Na+1]⁺ and [M+Na+2]⁺.

Example 7 Conjugation of Azido-PEG₃-S-S-Conjugated Sirolimus-GlyMolecule with DBCO-PEG₄-NHS Crosslinker

Azido-PEG₃-S-S-conjugated sirolimus-Gly molecule was dissolved in 100%DMSO at a final concentration of 10 mM, and DBCO-PEG₄-NHS crosslinkerwas dissolved in 100% DMSO at a final concentration of 250 mM. 4 μl ofthe DBCO-PEG₄-NHS crosslinker solution was added to 50 μl of theazido-PEG₃-S-S-conjugated sirolimus-Gly solution at a finalconcentration of 4 mM, so that the final molar ratio of DBCO-PEG₄-NHS toazido-PEG₃-S-S-conjugated sirolimus-Gly is 2:1. The reaction mixture wasincubated for 3 hours at room temperature for the SPAAC reaction.

FIG. 10A shows the mass spectrometric analysis of the thus-synthesizedNHS-PEG₄-PEG₃-S-S-conjugated sirolimus-Gly, as illustrated below (thediamond symbol represents a condensation product of SPAAC). MS (ESI)calculated for C₉₈H₁₄₀N₈O₂₈S₂ 1942.33; found 1941.9267, corresponding to[M+H]⁺. The four isotopic peaks were also visible in the MS spectrum at1942.9299, 1943.9328, 1944.9349 and 1945.9371, corresponding to[M+H+1]⁺, [M+H+2]⁺, [M+H+3]⁺, and [M+H+4]⁺.

FIG. 10B shows the mass spectrometric analysis of the thus-synthesizedNHS-PEG₄-PEG₃-S-S-conjugated sirolimus-diGly, as illustrated below (thediamond symbol represents a condensation product of SPAAC). MS (ESI)calculated for C₁₀₀H₁₄₃N₉O₂₉S₂ 1999.38; found 1998.9514, correspondingto [M+H]⁺. The four isotopic peaks were also visible in the MS spectrumat 1999.9546, 2000.9571, 2001.9591 and 2002.9609, corresponding to[M+H+1]⁺, [M+H+2]⁺, [M+H+3]⁺, and [M+H+4]⁺.

Example 8 Conjugation of Azido-PEG₃-S-S-Conjugated Fingolimod Moleculewith NHS-PEG₄-DBCO Crosslinker

Azido-PEG₃-S-S-conjugated fingolimod molecule was dissolved in 100% DMSOat a final concentration of 10 mM, and NHS-PEG₄-DBCO crosslinker wasdissolved in 100% DMSO at a final concentration of 250 mM. 5 μl of theNHS-PEG₄-DBCO crosslinker solution was added to 400 μl of theazido-PEG₃-S-S-conjugated fingolimod solution to a final molar ratio of1/3.2 (NHS-PEG₄-DBCO: azido-PEG₃-S-S-conjugated fingolimod) in 100 mMsodium phosphate buffer at pH 7.5 (final concentration: 10 mM). Thereaction mixture was incubated for 3 hours at room temperature for SPAACreaction.

FIG. 11 shows mass spectrometric analysis of the thus-synthesizedNHS-PEG₄-PEG₃-S-S-conjugated fingolimod, as illustrated below (thediamond symbol represents a condensation product of SPAAC). MS (ESI)calculated for C₆₄H₉₂N₇O₁₆S₂ 1278.5938; found 1278.613, corresponding to[M+H]⁺. The two isotopic peaks were also visible in the MS spectrum at1279.640 and 1280.635, corresponding to [M+H+1]⁺ and [M+H+2]⁺.

Example 9 Conjugation of NHS-PEG₄-PEG₃-S-S-Conjugated Sirolimus-Gly toTCO-Peptide 2

TCO-peptide 2 was dissolved in 100 mM sodium phosphate buffer at pH 7.5to a final concentration of 20 mM, and NHS-PEG₄-PEG₃-S-S-conjugatedsirolimus-Gly was dissolved in 100% DMSO to a final concentration of 10mM. 1.5 μl of TCO-peptide 2 and 60 μl of NHS-PEG₄-PEG₃-S-S-conjugatedsirolimus-Gly were mixed at a molar ratio of 1:20 (TCO-peptide 2:NHS-PEG₄-PEG₃-S-S-conjugated sirolimus-Gly). Then, 3.5 μl of a buffersolution containing 100 mM sodium phosphate buffer at pH 10 and 35 μl of100% DMSO were added to the reaction mixture to reach a total volume of100 μl, and the reaction mixture was incubated for 3 hours at roomtemperature.

FIG. 12A shows that the thus-synthesized drug bundle, as illustratedbelow, had a molecular weight of 11,562 Daltons; it was composed of alinker unit with one free TCO functional group and a set of fivesirolimus-Gly molecules.

Example 10 Conjugation of NHS-PEG₅-conjugated Fingolimod Molecules toTCO-peptide 2 and 3

TCO-peptide 2 was dissolved in 100 mM sodium phosphate buffer at pH 7.5to a concentration of 20 mM, and NHS-PEG₅-conjugated fingolimod wasdissolved in 100% DMSO to a concentration of 50 mM. TCO-peptide 2 andNHS-PEG₅-conjugated fingolimod were mixed at a molar ratio of 1/42 andincubated for 3 hours at room temperature. Additional TCO-peptide 2 wassubsequently added to the reaction solution to a final molar ratio of1/13.5 (TCO-peptide 2: NHS PEG₅-conjugated fingolimod). The mixture wasfurther incubated for 3 hours at room temperature.

FIG. 12B shows that the drug bundle of TCO-peptide 2 with fingolimod hada molecular weight of 5,069 Daltons. The thus-synthesized drug bundle,as illustrated below, was composed of a linker unit with one free TCOfunctional group and a set of five fingolimod molecules.

TCO-peptide 3 was dissolved in 100 mM sodium phosphate buffer at pH 7.5to a concentration of 10 mM, and NHS-PEG₅-conjugated fingolimod wasdissolved in 100% DMSO to a concentration of 50 mM. TCO-peptide 3 andPEG₅-NHS-conjugated fingolimod were mixed at a molar ratio of 1/42 atroom temperature overnight.

FIG. 12C shows that the drug bundle of TCO-peptide 3 with fingolimod hada molecular weight of 9,478.958 Daltons, indicating that 10 fingolimodmolecules were conjugated to the TCO-peptide 3 linker unit. The presentdrug bundle, as illustrated below, was composed of a linker unit withone free TCO functional group and a set of ten fingolimod molecules.

Example 11 Conjugation of NHS-PEG₅-conjugated Fingolimod PhosphateMolecules to TCO-peptide 2

TCO-peptide 2 and NHS-PEG₅-conjugated fingolimod phosphate were mixed ata molar ratio of 1/42 in 100 mM sodium phosphate buffer at pH 7.5 atroom temperature for 3 hours.

Mass spectrometric analysis shows that the drug bundle of TCO-peptide 2with fingolimod phosphate had a molecular weight of 5,379.16 Daltons(FIG. 12D). The thus-synthesized drug bundle, as illustrated below, wascomposed of a linker unit with one free TCO functional group and a setof five fingolimod phosphate molecules as effector elements.

Example 12 Conjugation of NHS-PEG₄-PEG₃-S-S-Conjugated FingolimodMolecules to TCO-peptide2

In this example, five NHS-PEG₄-PEG₃-S-S-conjugated fingolimod moleculeswere attached to TCO-peptide 2. The conjugation ofNHS-PEG₄-PEG₃-S-S-conjugated fingolimod molecules to the NH₂ groups oflysine residues of the TCO-peptide 2 was performed following theprotocol set forth in the preceding example. The identification wascarried out by mass spectrometry MALDI-TOF.

The thus-synthesized drug bundle, as illustrated below, had a molecularweight of 7,815 Daltons; it was composed of a linker unit with one freeTCO functional group and a set of five fingolimod molecules.

Example 13 Production of Recombinant Human HLA-A1-IgG1.Fc,HLA-A2-IgG1.Fc and PD-1-IgG1.Fc by Expi293F Overexpression System

The gene-encoding sequence was placed in pG1K expression cassette. Theamino acid sequence of human HLA-A1-IgG1.Fc, HLA-A2-IgG1.Fc andPD-1-IgG1.Fc are set forth in SEQ ID NOs: 27 to 29, respectively.

To prepare recombinant proteins using a mammalian expression system, theoverexpression system based on Expi293F™ cell line was used forexperimentation. The system employed ExpiFectamine™ 293 transfection kit(Life Technologies, Carlsbad, USA) consisting of the Expi293F™ cellline, the cationic lipid-based ExpiFectamine™ 293 Reagent andExpiFectamine™ 293 transfection Enhancers 1 and 2, and the medium, whichwas part of the expression system (Gibco, New York, USA).

Expi293F cells were seeded at a density of 2.0×10⁶ viable cells/ml inExpi293F expression medium and maintained for 18 to 24 hours prior totransfection to ensure that the cells were actively dividing at the timeof transfection. At the time of transfection, 7.5×10⁸ cells in 255-mlmedium in a 2-liter Erlenmeyer shaker flask were transfected byExpiFectamine™ 293 transfection reagent. The transfected cells wereincubated at 37° C. for 16 to 18 hours post-transfection in an orbitalshaker (125 rpm) and ExpiFectamine™ 293 transfection enhancer 1 andenhancer 2 were added to the shaker flask, and incubated for 5 to 6days. Culture supernatants were harvested and scFv proteins in the mediawere purified using Protein A affinity chromatography. FIGS. 13A, 13Band 13C show SDS-PAGE analysis results of purified human HLA-A1-IgG1.Fc,HLA-A2-IgG1.Fc and PD-1-IgG1.Fc fusion protein (indicated by arrow),respectively.

Example 14 Production of Recombinant Human CTLA-4 and PD-L1 by Expi293FOverexpression System

The sequences of the recombinant human CTLA-4 and PD-L1 are provided inSEQ ID NOs: 30 and 31. The two proteins were designed to contain aflexible linker of GGGGSGGGGS and a terminal cysteine residue at theC-terminus.

The expression of the constructed gene in Expi293F cells was performedas in preceding Examples. The expressed CTLA-4 protein in the media waspurified using affinity chromatography with immobilized antibodyspecific for CTLA-4. The expressed PD-L1 protein in the media waspurified using affinity chromatography with immobilized PD-1.

Characterization of the molecular construct was performed with 12%SDS-PAGE. The SDA-PAGE results in FIGS. 14A and 14B show that thepurified CTLA-4 and PD-L1 proteins have a size of about 26 and 32 kDa(indicated by arrow), respectively, consistent with the their expectedsizes.

Recombinant CTLA-4 protein was analyzed and detected using westernblotting. Briefly, 50 μl of the purified CTLA-4 protein waselectrophoresed on the 12% SDS-PAGE gel (lane 2) and electroblotted overto a PDVF membrane. The protein (CTLA-4)-IgG1Fc-(scFv α HLA-A1) was usedas a positive control (lane 1). After blocking with 5% BSA in TBST atroom temperature for 1 hour, the diluted scFv specific for CTLA-4 (1μg/ml) was added and incubated with the membrane overnight at 4° C. withgentle shaking. The membrane was rinsed and washed 3 times with TBST.The diluted HRP-conjugated protein L (1:5000) was added and incubatedwith the membrane at room temperature for 1 hour, and the rinse and washcycle was repeated with TBST for 3 times. The membrane was thenincubated with HRP substrate solution for 20 minutes before beingexposed to the photographic film.

FIG. 14C shows the western blot results indicating that the recombinanthuman CTLA-4 can be specifically bound by the scFv specific for CTLA-4(indicated by arrow of lane 2). The scFv specific for CTLA-4 wasprepared in our laboratory described in PCT patent applicationpublication No. WO/2016112870.

Binding activity of recombinant PD-L1 protein was assayed with ELISAusing a 96-well plate coated with recombinant PD-L1 protein in 50 μg/mlconcentration, 100 μl per well. After the excess PD-L1 was washed offand the solid phase blocked, 100 μl per well of PD1-IgG1.Fc at 50 μg/mlwas added. The bound PD1-IgG1.Fc was determined by HRP-conjugated goatanti-human IgG.Fc. 50 μl of TMB substrate was added for colordevelopment. The reaction was stopped by 50 μl of 1M HCl. Absorbance at450 nm was measured with a plate reader. Each bar represents the meanOD450 value of duplicate samples.

FIG. 14D shows the ELISA results indicating that the recombinant humanPD-L1 specifically bound to recombinant PD1-IgG1.Fc.

Example 15 Production of scFv of mAb Specific for HLA-A1 and mAbSpecific for CD25 by Expi293F Overexpression System

The V_(L) and V_(H) of the scFv specific for human HLA-A1 were frommonoclonal antibody 4-35-7; the V_(L) and V_(H) of the scFv specific forhuman CD25 were from monoclonal antibody dacilizumab. The scFv derivedfrom those antibodies were designed to contain a flexible linker ofGGGGSGGGGS and a terminal cysteine residue at the C-terminus. Thecysteine residue provides a sulfhydryl group for conjugation withmaleimide group present at the free ends of linking arms in variouslinker units. To produce the scFv of mAb specific for human HLA-A1 andmAb specific for human CD25, we used the V_(L) and V_(H) DNA sequencesof the two antibodies with further codon optimization. DNA sequencesencoding V_(L)-(GGGGS)₃-V_(H)-(GGGGS)₂-C were synthesized. The aminoacid sequences of the scFv of mAb specific for human HLA-A1, and mAbspecific for human CD25 prepared for the experiments of the inventionare set forth in SEQ ID NOs: 32 and 33, respectively.

The expression of the constructed gene in Expi293F cells was performedas in preceding Examples. Culture supernatants were harvested and scFvproteins in the media were purified using Protein L affinitychromatography. FIGS. 15A, 15B and 15C show 12% SDS-PAGE, massspectrometric and ELISA analyses of purified scFv of mAb specific forhuman HLA-A1. The SDA-PAGE results in FIG. 15A shows that the purifiedscFv of mAb specific for human HLA-A1 has a size of about 25 kDa(indicated by arrow), consistent with the their expected sizes. TheELISA result in FIG. 15C indicates that the purified scFv of mAbspecific for human HLA-A1 bound specifically to human HLA-A1. The scFvspecific for TNF-α was used as a negative control, which was prepared asdescribed in PCT patent application publication No. WO/2016112870.

Example 16 Construction and Selection of Phage-displayed scFvs Specificfor Human HLA-A2

The phage clones carrying human scFv specific for human HLA-A2 wereobtained through a contractual arrangement with Dr. An-Suei Yang'slaboratory at the Genomics Research Center, Academia Sinica, Taipei,Taiwan. The framework sequence of the GH2 scFv library was derived froma human IgG antibody fragment, G6 anti-VEGF Fab (Protein Bank Code2FJG), and cloned into restriction sites SfiI and NotI of phagemidvector pCANTAB5E (GE Healthcare), carrying an ampicillin resistance, alacZ promotor, a pelB leader sequence for secretion of scFv fragmentsinto culture supernatants, and an E-tag applicable for detection. TheV_(H) and V_(L) domains of the scFv template were diversified separatelybased on the oligonucleotide-directed mutagenesis procedure; the threeCDRs in each of the variable domains were diversified simultaneously.The scFv library of over 10⁹ clones was used for selections on humanHLA-A2-IgG.Fc fusion protein prepared in the preceding Example.

Maxisorp 96-well plates (Nunc) coated with recombinant humanHLA-A2-IgG1.Fc fusion proteins (1 μg/100 μl PBS per well) were used forpanning anti-HLA-A2 antibodies. Briefly, the wells were treated withblocking buffer (5% skim milk in PBST (phosphate buffered saline with0.1% tween-20)) for 1 hour at room temperature. Recombinant phages inthe blocking buffer diluted to 6×10¹¹ CFU/ml was added to theantigen-coated wells for 1 hour with gentle shaking; CFU stands forcolony-forming unit. The wells were then washed vigorously 10 times withPBST, followed by 6 times with PBS to remove nonspecific binding phages.The bound phages were eluted using 0.1 M HCl/glycine buffer at pH 2.2,and the eluted fraction was neutralized immediately by 2 M Tris-basebuffer at pH 9.0. E. coli strain ER2738 (OD600=˜0.6) was used for phageinfection at 37° C. for 30 minutes; non-infected E. coli was eliminatedby treating with ampicillin for 30 minutes. After ampicillin treatment,helper phage M13KO7 carrying kanamycin resistance was added for anotherone-hour incubation. The selected phages rescued by helper phage in theE. coli culture were amplified under vigorously shaking overnight at 37°C. in the presence of kanamycin. The amplified phages were precipitatedin PEG/NaCl, and then resuspended in PBS for the nextselection-amplification cycle. A total of three consecutive panningrounds were performed on human HLA-A2 by repeating thisselection-amplification procedure.

Phage-infected ER2738 colonies were enumerated by serial dilution andphage titers were calculated, yielding the output titer/ml (CFU/ml) perpanning round. A 2500-fold increase in phage output titer from 4.0E+05CFU/well to 1.0E+09 CFU/well was obtained after three rounds of panning.The phage output/input titer ratios from each round are shown in FIG.16A. For each panning round, the phage output/input titer ratios aregiven on the y-axis. There was clear enrichment of the positive clonesover the three rounds of panning. The third panning round resulted in a300-fold increase in the ratios of phage output/input titer over thefirst round, as the binding clones became the dominant population in thelibrary.

Example 17 Single Colony ELISA Analysis of Phage-displayed scFvsSpecific for Human HLA-A2

E. coli strain ER2738 infected with single-clonal phages each harboringa selected scFv gene in its phagemid was grown in the mid-log phase in2YT broth (16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl, pH 7.0)with 100 μg/ml ampicillin in deep well at 37° C. with shaking. After thebroth reached an OD600 of 1.0, IPTG was added to a final concentrationof 1 μg/ml. The plates were incubated at 37° C. overnight underrigorously shaking. Thereafter, the plates were centrifuged at 4,000 gfor 15 minutes at 4° C.

For soluble scFv binding test, ELISA was carried out. Briefly, 96-wellMaxisorp 96-well plate (Nunc) was coated with human HLA-A2 (0.5 μg/100μl PBS per well) or two negative control antigens, human heat shockprotein 70 (Hsp 70) and RSV-IgG1.Fc fusion protein (prepared by ourlaboratory), for 18 hours with shaking at 4° C. After being treated with300 μl of blocking buffer for 1 hour, 100 μl of secreted scFv in thesupernatant was mixed with 100 μl of blocking buffer and then added tothe coated plate for another 1 hour. Goat anti-E-tag antibody(conjugated with HRP, 1:4000, Cat. No. AB19400, Abcam) was added to theplate for 1 hour. TMB substrate (50 μl per well) was added to the wellsand the absorbance at 450 nm was measured after reactions were stoppedby adding 1N HCl (50 μl per well).

A total of 192 phage clones after the 3^(rd) round of panning weresubjected to the present analysis. Among them, 12 scFv clones that boundto HLA-A2 with a differential of OD450 greater than 10 were furthercharacterized by DNA sequencing of their encoding scFv genes. Eightdifferent DNA sequences were identified. FIG. 16B shows the ELISA resultof one scFv clone, 3E10. The amino acid sequence of the scFV clone 3E10,which binds to human HLA-A2 with an OD450 of 1.3, is provided in SEQ IDNO: 34.

Example 18 Preparation of Tetrazine-scFv Specific for Human HLA-A1

The DNA sequence encoding the scFv specific for human HLA-A1 (SEQ ID NO:32) was synthesized and expressed as in the above Examples. For theconjugation with Mal-PEG₄-tetrazine (Conju-probe, Inc.), the cysteineresidue at the C-terminal end of the purified scFv of mAb specific forhuman HLA-A1 was reduced by incubating with 10 μM TCEP at roomtemperature for 4 hours with gentle shaking. The buffer of reduced scFvproteins were exchanged to sodium phosphate buffer (100 mM sodiumphosphate, pH 7.0, and 50 mM NaCl) using NAP-10 Sephadex G-25 column.After the reduction reaction and buffer exchange, conjugation wasconducted overnight at 4° C. in a reaction molar ratio of 10:1([Mal-PEG₄-tetrazine:[scFv]]. The excess crosslinker was removed by adesalting column and the tetrazine-conjugated scFv products wereanalyzed.

The results of mass spectroscopy MALDI-TOF analysis indicated that thesample of tetrazine-conjugated scFv specific for human HLA-A1 had amolecular weight of 27,462 Daltons. The purity of tetrazine-conjugatedscFv specific for human HLA-A1 was identified through Coomassie bluestaining of 12% SDS-PAGE. FIGS. 17A and 17B show, respectively, the massspectrometric and ELISA analysis of tetrazine-conjugated scFv specificfor human HLA-A1, in which unmodified scFv specific for human HLA-A1 wasused as a positive control. The ELISA results establish that thetetrazine-conjugated scFv specific for human HLA-A1 bound to recombinantHLA-A1.

Example 19 Conjugation of Three CTLA-4 Molecules to ThreeMaleimide-PEG₁₂ Linking Arms Based on TCO-Peptide 1

Prior to being conjugated with the TCO-peptide 1 that had threemaleimide-PEG₁₂ linking arms, CTLA-4 was incubated with TCEP at a molarratio of 2:1 ([TCEP]:[protein]) at room temperature for 4 hours undergentle shaking to keep its C-terminal cysteine in the reduced form.Subsequently, the buffer of the reduced CTLA-4 protein was exchanged tomaleimide-SH coupling reaction buffer (100 mM sodium phosphate, pH 7.0,and 50 mM NaCl) using an NAP-10 Sephadex G-25 column (GE Healthcare).After the reduction and buffer exchange, the conjugation to theTCO-peptide 1 having three maleimide-PEG₁₂ linking arms was conductedovernight at room temperature at a molar ratio of 1:4([linker]:[Protein]).

The reaction mixture was applied to a size exclusion chromatographycolumn S75. The PEG₁₂-maleimide-conjugated TCO-peptide 1 conjugated withthree CTLA-4 molecules was separated from the free CTLA-4, freePEG₁₂-maleimide-conjugated TCO-peptide 1 and thePEG₁₂-maleimide-conjugated TCO-peptide 1 conjugated with one and twoCTLA-4 molecules by size exclusion chromatography column S75. Thepurified product, maleimide-PEG₁₂-conjugated TCO-peptide 1 conjugatedwith three CTLA-4 molecules, was concentrated and buffer-exchange intoclick reaction buffer, 100 mM potassium phosphate at pH 7.0.

Illustrated below is the thus-synthesized effector linker unit that wascomposed of a linker unit with one free TCO functional group and a setof three CTLA-4 molecules as effector elements.

Example 20 SDS-PAGE Analysis of Effector Linker Unit Containing ThreeCTLA-4 Molecules Linked to Three Maleimide-PEG₁₂ Linking Arms Based onTCO-peptide 1

The sample of the effector linker unit having three CTLA-4 moleculeslinked to the three maleimide-PEG₁₂ linking arms based on TCO-peptide 1was analyzed by 8% SDS-PAGE. The size of the experimental molecularweight was consistent with the size of theoretical molecular weight ofthree CTLA-4 molecules conjugated to TCO-peptide 1 with threemaleimide-PEG₁₂ linking arms. The SDS-PAGE analysis of the reactionmixtures of TCO-peptide 1 with three maleimide-PEG₁₂ linking arms afterthe conjugation with CTLA-4 molecules. The product was subjected to 10%SDS-PAGE analysis, and the result indicated a weak band corresponding toTCO-peptide 1 conjugated with three CTLA-4 molecules.

Example 21 Preparation of Effector Linker Unit Based on TCO-peptide 1with Three PD-L1 Molecules

The conjugation of human PD-L1 to the linker unit and the purificationand analysis of the product were performed per the protocols set forthin the preceding Examples.

FIG. 18 shows the 10% SDS-PAGE analysis of the reaction mixtures ofTCO-peptide 1 with three maleimide-PEG₁₂ linking arms after theconjugation with PD-L1 molecules (lane 1). Arrow #1 and #2 wereTCO-peptide 1 conjugated with three and two PD-L1 molecules,respectively.

The sample of the effector linker unit of three PD-L1 linked to thethree maleimide-PEG₁₂ linking arms based on TCO-peptide 1 was analyzedby MALDI-TOF. The median of the experimental molecular weight wasconsistent with the median of theoretical molecular weight of threePD-L1 conjugated to TCO-peptide 1 with three maleimide-PEG₁₂ linkingarms. Illustrated below is the thus-synthesized effector linker unitthat was composed of a linker unit with one free TCO functional groupand a set of three PD-L1 molecules as effector elements.

Example 23 Preparation of Effector Linker Unit Based on TCO-peptide 1with Three scFv Specific for Human CD25 Molecule

The conjugation of scFv specific for human CD25 to the linker unit andthe purification and analysis of the product were performed per theprotocols set forth in the preceding Examples.

Illustrated below is the thus-synthesized effector linker unit that wascomposed of a linker unit with one free TCO functional group and a setof three scFvs specific for the extracellular domain of human CD25 aseffector elements.

Example 22 Preparation of Molecular Construct with One scFv Specific forHLA-A1 as Targeting Elements and Three CTLA-4 Molecules as EffectorElement

In this example, the effector linker unit of the preceding examples anda tetrazine-conjugated scFv specific for human HLA-A1 was coupled via atetrazine-TCO iEDDA reaction. Specifically, the effector linker unit hadthree CTLA-4 molecules and one free TCO group.

The procedure for tetrazine-TCO ligation was performed per themanufacturer's instructions (Jena Bioscience GmbH, Jena, Germany).Briefly, 100 μl of the targeting linker unit (0.3 mg/ml) was added tothe solution containing the effector element at a molar ratio of 1.2:1([tetrazine]:[TCO]). The reaction mixture was incubated for 3 hour atroom temperature.

In the mass spectrometric analysis, the median of the experimentalmolecular weight was consistent with the median of theoretical molecularweight of the resultant joint-linker molecular construct. Illustratedbelow is the resultant single-linker molecular construct with one scFvspecific for human HLA-A1 as targeting element and with three CTLA-4molecules as effector elements.

Example 23 Preparation of Molecular Construct with One scFv Specific forHLA-A1 as Targeting Elements and Three PD-L1 Molecules as EffectorElement

In this example, the effector linker unit of the preceding examples anda tetrazine-conjugated scFv specific for human HLA-A1 was coupled via atetrazine-TCO iEDDA reaction. Specifically, the effector linker unit hadthree PD-L1 molecules and one free TCO group. The procedure fortetrazine-TCO ligation was the same as in the preceding Examples.

Illustrated below is the resultant single-linker molecular constructwith one scFv specific for human HLA-A1 as targeting element and withthree PD-L1 molecules as effector elements.

FIG. 19 shows 10% SDS-PAGE analysis of the reaction mixtures ofresultant single-linker molecular construct with one scFv specific forhuman HLA-A1 as targeting element and with three PD-L1 molecules aseffector elements (lane 2). The lane 1 showed that the reaction mixturesof TCO-peptide 1 with three maleimide-PEG₁₂ linking arms after theconjugation with PD-L1 molecules. Arrow #1 (lane 2) was thesingle-linker molecular construct with one scFv specific for humanHLA-A1 as targeting element and with three PD-L1 molecules as effectorelements. Arrow #2 and #3 were respectively TCO-peptide 1 conjugatedwith three and two PD-L1 molecules.

Example 24 Preparation of Molecular Construct with One scFv Specific forHLA-A1 as Targeting Elements and Three scFvs Specific for Human CD25 asEffector Element

In this example, the effector linker unit of the preceding examples anda tetrazine-conjugated scFv specific for human HLA-A1 was coupled via atetrazine-TCO iEDDA reaction. Specifically, the effector linker unit hadthree scFvs specific for the extracellular domain of human CD25 and onefree TCO group. The procedure for tetrazine-TCO ligation was the same asin the preceding Examples.

Illustrated below is the resultant joint-linker molecular construct withone scFv specific for human HLA-A1 as targeting element and with threescFvs specific for the extracellular domain of human CD25 as effectorelements.

Example 25 Preparation of Molecular Construct with One scFv Specific forHLA-A1 as Targeting Element and Five Sirolimus-Gly Molecules as EffectorElements

In this example, the molecular construct with one scFv specific forhuman HLA-A1 and a drug bundle of five sirolimus-Gly molecules wasconstructed. The molecular construct was made by a TCO-tetrazine iEDDAreaction. The procedure for tetrazine-TCO ligation was the same as inthe preceding Examples.

The MALDI-TOF mass spectrometric analysis showed that the median of theexperimental molecular weight was consistent with the median oftheoretical molecular weight of the resultant joint-linker molecularconstruct. The product, as illustrated below, was the molecularconstruct with one scFv specific for human HLA-A1 and one drug bundlebearing five sirolimus-Gly molecules.

Example 26 Preparation of Molecular Construct with One scFv Specific forHLA-A1 as a Targeting Element and Five Fingolimod Molecules as EffectorElements

In this example, the molecular construct with one scFv specific forhuman HLA-A1 and a drug bundle of five fingolimod molecules wasconstructed. The molecular construct was made by a TCO-tetrazine iEDDAreaction. The procedure for tetrazine-TCO ligation was the same as inthe preceding Examples.

The median of the experimental molecular weight was consistent with themedian of theoretical molecular weight of the resultant joint-linkermolecular construct. The product, as illustrated below, was themolecular construct with one scFv specific for human HLA-A1 and one drugbundle bearing five fingolimod molecules.

Example 27 Assay of Biological Activity of Sirolimus Upon Conjugationwith NHS-S-S-PEG₃-azido Linking Arm

Mammalian target of rapamycin (mTOR) is a protein kinase that controls Tcell activation and proliferation. Sirolimus, also known as rapamycin,inhibits mTOR indirectly by binding to immunophilin, FK binding protein(FKBP12). The complex of rapamycin and FKBP12 then interacts with mTORand inhibits the function to phosphorylate its downstream target, p70 S6Kinase (p70S6K), leading to inhibition of cell activation andproliferation.

The syntheses of these modified sirolimus molecules (sirolimus-Gly,sirolimus-diGly and azido-PEG₃-S-S-conjugated sirolimus-Gly) have beenshown in the preceding examples. To examine the biological activities ofthese compounds, western blot analysis of mTOR/p70S6K signaling pathwayand T-cell proliferation assay were performed with human Jurkat T cells.T-cell viability and proliferation were assessed using alamarBlue® cellviability reagent (Invitrogen).

For the western blot analysis of mTOR/p70S6K signaling pathway, briefly,Jurkat T cell were seeded into 6-cm cell culture dish in RPM11640 mediumcontaining 10% fetal bovine serum. After 1 hour, cells were co-treatedwith 10 ng/ml of IL2 and 100 nM of sirolimus, sirolimus-Gly,azido-PEG₃-S-S-conjugated sirolimus-Gly, and sirolimus-diGly for 24hours.

The cells were then lysed in gold lysis buffer, containing 30 mMTris-HCl, (pH 7.9), 5 mM EGTA, 137 mM NaCl, 15% glycerol, 1% TritonX-100, and 1× protease inhibitor cocktail. Insoluble material wascollected by centrifugation at 14,000×g for 20 minutes at 4° C. The celllysate samples were separated on 10% SDS-PAGE gels and transferred to aPVDF membrane (Millipore). The membrane blots were blocked in PBScontaining 5% BSA for 1 hour at room temperature, and incubated withprimary antibodies, anti-phospho-p70S6K antibody (Cell SignalingTechnology, Danvers, USA) and anti-p70S6K antibody (Cell SignalingTechnology), overnight at 4° C. After washing three times with TBSTcontaining 20 mM Tris-HCl (pH 7.6), 0.8% (w/v) NaCl and 0.25% Tween-20,the blots were incubated with goat anti-mouse IgG.Fc antibody conjugatedwith horseradish peroxidase (Millipore). Then the membranes were washedthree times with TBST, and immunoreacted bands were detected with ECL™western blotting detection reagents (Millipore) and exposed on Fujifilm(Tokyo, Japan). Relative quantification of ECL signals on X-ray filmswere analyzed by using Image J (NIH, Bethesda, Md., USA).

FIG. 20A shows the effect of sirolimus, sirolimus-Gly, sirolimus-diGlyand azido-PEG₃-S-S-conjugated sirolimus-Gly on mTOR protein in Jurkat Tcells by western blot analysis. As showed in FIG. 20A, thephosphorylated level of p70S6K was decreased in the cells treated withsirolimus and sirolimus derivative compounds, without changes in thetotal p70S6K protein level. The result indicates that the mTOR/p70S6Ksignally pathway in the treated T cells was blocked by sirolimusderivative compounds, having a similar effect as the unmodifiedsirolimus.

For T-cell proliferation assay, Jurkat T cells (2*10⁴/well) were seededinto 96-well plates in RPMI1640 medium containing 10% fetal bovineserum. After 1 hour, cells were treated with or without 10 ng/ml of IL2.After incubating for 24 hours, cells were then treated with differentconcentrations (2 folds dilution from 200 nM) of sirolimus,sirolimus-Gly, azido-PEG₃-S-S-conjugated sirolimus-Gly, andsirolimus-diGly for 24 hours, 48 hours, and 72 hours. Cells viabilitywas determined by alamarBlue cell viability reagent kit (Invitrogen), inaccordance with the manufacturer's instruction.

FIG. 20B shows the assay results of the biological activity ofsirolimus, sirolimus-Gly, sirolimus-diGly and azido-PEG₃-S-S-conjugatedsirolimus-Gly. The result indicates that the sirolimus derivativecompounds had similar biological activity to inhibit mTOR activity asthe unmodified sirolimus.

Example 28 Assay of Biological Activity of Fingolimod Upon Conjugationto Peptide Core Through Linking Arms

Fingolimod has been used as a functional antagonist of shingosine-1phosphate (S1P) receptor-1 (S1P₁) function, thereby cells expressingS1P₁ receptors that are pretreated with fingolimod are renderedunresponsive to subsequent S1P stimulation (Pedro J. et al., 2012).Fingolimod's capacity to modulate S1P₁ function rely on its ability torapidly internalize S1P₁ from a membrane to a cytoplasmic compartment,thus rendering cells unable to respond to external S1P signals. Recentdata has been shown that the phosphorylated form of fingolimod binds toS1P receptors and blocks T and B lymphocyte egress and circulation.

The syntheses of these modified fingolimod molecules(NHS-PEG₅-conjugated fingolimod and the drug bundle with one free TCOfunctional group and with five fingolimod molecules) have been shown inthe preceding examples. To examine the biological activities of thethree compounds, SiP-driven Transwell migration assay was performed withhuman primary B cells isolated from human PBMC (peripheral bloodmononuclear cells).

In the preparation of human primary B cells, human B cells were isolatedfrom human PBMC (peripheral blood mononuclear cells) by B cell isolationkit (Myltenyi Biotech). The isolated B cells were seeded and maintainedin a 15-cm dish in IMDM medium supplemented with 10% fetal bovine serum(Gibco) and 20 ng/ml IL2 (Peprotech Inc.).

FIG. 21A shows that staining analysis of the isolated S1P₁receptor-expressing human B cells, 2×10⁵ B cells were incubated with 10μg/ml of anti-S1P₁ receptor antibody (AbD Serotec) in PBS containing 1%BSA on ice for 30 minutes. Cells were washed and incubated withFITC-conjugated goat anti-mouse IgG, diluted 1:200 in PBS/BSA, on icefor 30 minutes in the dark. The cells were then analyzed by FACS(FACSCanto II, BD Biosciences).

For chemotaxis assays, 100 μl of the maintained human B cells (4×10⁵cells) were transferred into 1.5-ml Eppendorf tube and added fingolimod,fingolimod phosphate, NHS-PEG₅-conjugated fingolimod, and the drugbundle with one free TCO functional group and with five fingolimodmolecules, respectively, at a final concentration of 1 and 10 μM at 37°C. for 4 hours. Subsequently, the treated B cells of 100 μl were addedto the upper chamber of a 6.5 mm Trans-well with 5 μm pore polyestermembrane insert (Corning), and the lower chamber of the Trans-well hadcontained 500 μl of IMDM medium with S1P at a final concentration of 10nM. After 3 hours, the migrated cells in the lower chambers werecollected and further stained with trypan blue and counted byhemocytometer. For each measurement, the specific migration wascalculated as follows: [(Number of cells in lower chamber)/(Number ofcells in lower+upper chamber)×100]−(cell migration percentage at 0 nMattractant)]. The result of the percentage of specific migrated cells isshown in FIG. 21B.

FIG. 21B shows the assay results of the biological activity ofNHS-PEG₅-conjugated fingolimod and the drug bundle with one free TCOfunctional group and with five fingolimod molecules. The resultindicates that the fingolimod molecule conjugated with a linking arm hadsimilar biological activity to block B-cell migration as the unmodifiedfingolimod.

Example 29 Construction of a Gene Segment Encoding 2-chain IgG1.FcFusion Protein Containing CTLA-4 and scFv Specific for HLA-A1

Abatacept is a fusion protein composed of the Fc region of the humanIgG1 fused to the extracellular domain of CTLA-4. The 2-chain IgG.Fcfusion protein was prepared by configuring abatacept-(scFv α HLA-A1) ina recombinant chain. The C-terminal of the abatecept was fused to theN-terminal of the scFv 4-35-7 specific for human HLA-A1 via a flexiblelinker, (GGGGS)₂.

The scFv (specific for human HLA-A1) had an orientation ofV_(L)-linker-V_(H). The V_(L) and V_(H) in the scFv were connected by ahydrophilic linker, (GGGGS)₃. The sequence of the recombinant chain inthe IgG1.Fc fusion protein molecular construct is shown as SEQ ID NO:35.

Illustrated below is the configuration of the prepared 2-chainCTLA-4-hIgG1.Fc-(scFv α HLA-A1) molecular construct

Example 30 Expression and Purification of Recombinant 2-chainCTLA-4-hIgG1.Fc-(scFv α HLA-A1) Fusion Protein

In this Example, the gene-encoding sequence was placed in pcDNA3expression cassette. Expi293F cells were seeded at a density of 2.0×10⁶viable cells/ml in Expi293F expression medium and maintained for 18 to24 hours prior to transfection to ensure that the cells were activelydividing at the time of transfection. At the time of transfection,7.5×10⁸ cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask weretransfected by ExpiFectamine™ 293 transfection reagent. The transfectedcells were incubated at 37° C. for 16 to 18 hours post-transfection inan orbital shaker (125 rpm) and the cells were added ExpiFectamine™ 293transfection enhancer 1 and enhancer 2 to the shaker flask, andincubated for 7 days. Culture supernatants were harvested andrecombinant 2-chain CTLA-4-hIgG1.Fc-(scFv α HLA-A1) fusion protein inthe media was purified using Protein A chromatography. Following bufferexchange to PBS, the concentration of CTLA-4-hIgG1.Fc-(scFv α HLA-A1)protein was determined and analyzed by 8% SDS-PAGE shown in FIG. 22A.The Fc-fusion molecular construct was revealed as the major bandindicated by arrow at about 72 kDa (indicated by arrow), consistent withthe expected size.

Example 31 ELISA Analysis of the Binding of Recombinant 2-chainCTLA-4-hIgG1.Fc-(scFv α HLA-A1) Fusion Protein

Binding activity of recombinant CTLA-4-hIgG1.Fc-(scFv α HLA-A1) to wasassayed by ELISA using a 96-well plate coated with recombinantCTLA-4-hIgG1.Fc-(scFv α HLA-A1) protein in 5 μg/ml concentration, 100 μlper well. The (scFv α endotoxin)-hIgG1.Fc-(scFv α CD32a) prepared by ourlaboratory is used as a negative control.

After treated with 200 μl of blocking buffer for 1 hour, 100 μl ofanti-CTLA-4 scFv was added to the coated plate for another 1 hour. Then,HRP-conjugated Protein L (1:5000) was added to the coated plate for 1hour. Next, 50 μl of TMB substrate was added for color development. Thereaction was stopped by 50 μl of 1M HCl. Absorbance at 450 nm wasmeasured with a plate reader. Each bar represents the mean OD450 valueof duplicate samples.

FIG. 22B shows ELISA analysis of the present the molecular construct.The ELISA results show that CTLA-4-hIgG1.Fc-(scFv α HLA-A1) fusionprotein was bound specifically by scFv specific for CTLA-4. The scFvspecific for CTLA-4 was prepared in our laboratory described in PCTpatent application publication No. WO/2016112870.

Binding activity of recombinant CTLA-4-hIgG1.Fc-(scFv α HLA-A1) to wasassayed by ELISA using a 96-well plate coated with recombinant HLA-A1protein in 5 μg/ml concentration, 100 μl per well. The GST protein (asample from Dr. Kuo I Lin, Genomics Research Center, Academia Sinica,Taipei, Taiwan) was used as a negative control.

After treated with 200 μl of blocking buffer for 1 hour, 100 μl ofrecombinant CTLA-4-hIgG1.Fc-(scFv α HLA-A1) in 5 μg/ml concentration wasadded to the coated plate for another 1 hour. Then, HRP-conjugated goatanti-human IgG.Fc (1:2000) was added to the coated plate for 1 hour.Next, 50 μl of TMB substrate was added for color development. Thereaction was stopped by 50 μl of 1M HCl. Absorbance at 450 nm wasmeasured with a plate reader. Each bar represents the mean OD450 valueof duplicate samples.

FIG. 22C shows ELISA analysis of the present the molecular construct.The ELISA results show that CTLA-4-hIgG1.Fc-(scFv α HLA-A1) fusionprotein was bound specifically to human HLA-A1.

Example 32 Preparation of Recombinant 2-chain (PD-L1)-hIgG4.Fc-(scFv αHLA-A1) Fusion Protein

The PD-L1-CH2-CH3-scFv (human γ4) recombinant chain was configured byfusing human PD-L1 to the N-terminal of CH2 domain of IgG4.Fc through aflexible hinge region, and the scFv 4-35-7 specific for human HLA-A1 wasfused to the C-terminal of CH3 domain through a flexible linker,(GGGGS)₃.

The scFvs had an orientation of V_(L)-linker-V_(H). The V_(L) and V_(H)in the scFv was connected by a hydrophilic linker, (GGGGS)₃. Thesequence of the recombinant chain in the IgG4.Fc fusion proteinmolecular construct is shown as SEQ ID NO: 36.

Characterization of the new construct was performed with SDS-PAGE andELISA. The SDA-PAGE results in FIG. 23A shows that the recombinant chainof the new construct has a size of about 80 kDa (indicated by arrow),consistent with the expected size.

Binding activity of recombinant (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) wasassayed by ELISA using a 96-well plate coated with recombinant(PD-L1)-hIgG4.Fc-(scFv α HLA-A1) protein in 5 μg/ml concentration, 100μl per well. After the excess (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) waswashed off and the solid phase blocked, 100 μl per well of anti-PD-L1antibody at 5 μg/ml was added. The bound anti-PD-L1 antibody wasdetermined by HRP-conjugated goat anti-human IgG.Fc. 50 μl of TMBsubstrate was added for color development. The reaction was stopped by50 μl of 1M HCl. Absorbance at 450 nm was measured with a plate reader.Each bar represents the mean OD450 value of duplicate samples. FIG. 23Bshows the ELISA result indicates that the mAb specific for human PD-L1(MPDL3280A, a sample from Dr. An Suei Yang, Genomics Research Center,Academia Sinica, Taipei, Taiwan) specifically bound to(PD-L1)-hIgG4.Fc-(scFv α HLA-A1).

Binding activity of recombinant (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) wasassayed by ELISA using a 96-well plate coated with recombinant(PD-L1)-hIgG4.Fc-(scFv α HLA-A1) protein in 10 μg/ml concentration, 100μl per well. After the excess (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) waswashed off and the solid phase blocked, 100 μl per well of PD1-IgG1.Fcat 10 μg/ml was added. The bound PD1-IgG1.Fc was determined byHRP-conjugated goat anti-human IgG.Fc (1:2000). 50 μl of TMB substratewas added for color development. The reaction was stopped by 50 μl of 1MHCl. Absorbance at 450 nm was measured with a plate reader. Each barrepresents the mean OD450 value of duplicate samples. FIG. 23C showsthat the recombinant human (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) specificallybound to recombinant (PD1)-hIgG1.Fc. The (reteplase)-hIgG4.Fc-(scFv αfibrin) fusion protein (prepared by our laboratory) was as a negativecontrol.

Binding activity of recombinant (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) tohuman HLA-A1 was assayed by ELISA using a 96-well plate coated withrecombinant human HLA-A1 protein in 10 μg/ml concentration, 100 μl perwell. After the excess HLA-A1 protein was washed off and the solid phaseblocked, 100 μl per well of (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) at 10 μg/mlwas added. The bound (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) was determined byHRP-conjugated goat anti-human IgG.Fc. 50 μl of TMB substrate was addedfor color development. The reaction was stopped by 50 μl of 1M HCl.Absorbance at 450 nm was measured with a plate reader. Each barrepresents the mean OD450 value of duplicate samples. FIG. 18D showsthat the recombinant human (PD-L1)-hIgG4.Fc-(scFv α HLA-A1) specificallybound to recombinant HLA-A1. The GST protein was used as a negativecontrol.

Illustrated below is the configuration of the prepared 2-chain(PD-L1)-hIgG4.Fc-(scFv α HLA-A1) molecular construct

Example 33 Construction of a Gene Segment Encoding 2-chain (scFv αCD25)-hIgG4.Fc-(scFv α HLA-A1) Fusion Protein

The V_(L) and V_(H) of the scFv specific for human CD25 were frommonoclonal antibody dacilizumab. The 2-chain IgG.Fc fusion protein wasprepared by configuring (scFv α CD25)-CH2-CH3-(scFv α HLA-A1) (human γ4)in a recombinant chain. The C-terminal of the scFv specific for humanCD25 was fused to the N-terminal of CH2 via a short linker, ASGGS. ThescFv specific for HLA-A1 was fused to the C-terminal of CH3 domainthrough a flexible linker, (GGGGS)₃.

The two scFv had the orientation of V_(L)-linker-V_(H). The V_(L) andV_(H) in each of the two scFv were connected by a hydrophilic linker,(GGGGS)₃. The sequence of the recombinant chain in the IgG4.Fc fusionprotein molecular construct is shown as SEQ ID NO: 37. The preparationof the Fc. Fusion protein was the same as described in the precedingExample.

Illustrated below is the configuration of the prepared 2-chain (scFv αCD25)-IgG4.Fc-(scFv α HLA-A1) molecular construct.

It will be understood that the above description of embodiments is givenby way of example only and that various modifications may be made bythose with ordinary skill in the art. The above specification, examples,and data provide a complete description of the structure and use ofexemplary embodiments of the invention. Although various embodiments ofthe invention have been described above with a certain degree ofparticularity, or with reference to one or more individual embodiments,those with ordinary skill in the art could make numerous alterations tothe disclosed embodiments without departing from the spirit or scope ofthis invention.

What is claimed is:
 1. A molecular construct comprising, a pair ofCH2-CH3 segments of an IgG.Fc; a pair of effector elements, wherein eacheffector element is an extracellular domain of cytotoxic T lymphocyteassociated protein 4 (CTLA-4) or an extracellular domain of programmeddeath-ligand 1 (PD-L1); and a pair of targeting elements, wherein eachtargeting element is an antibody fragment specific for a human leukocyteantigen (HLA) allotype present only on cells of a donor transplant andnot on cells of the recipient and comprises the amino acid sequence ofSEQ ID NO: 32 or SEQ ID NO: 34, wherein, the pair of effector elementsis linked to the N-termini of the pair of CH2-CH3 segments, and the pairof targeting elements is linked to the C-termini of the pair of CH2-CH3segments, or vice versa.
 2. The molecular construct of claim 1, whereinthe pair of CH2-CH3 segments is derived from human γ1 or γ4immunoglobulin.
 3. The molecular construct of claim 1, wherein the pairof targeting elements is in the form of an antigen-binding fragment(Fab) and is linked to the N-termini of the pair of CH2-CH3 segments, sothat the molecular construct adopts an IgG configuration.
 4. Themolecular construct of claim 1, wherein the molecular constructcomprises the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 36.